Diagnostic miRNA markers for Alzheimer

ABSTRACT

The invention relates to methods for diagnosing Alzheimer&#39;s Disease (AD) with miRNA markers. Diagnosis of AD Towards the identification of biomarkers for diagnosis of AD, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified.

PRIORITY STATEMENT

This application is a national phase application under 35 U.S.C. § 371 of PCT International Application No. PCT/EP2013/072567 which has an International filing date of 29 Oct. 2013, which designated the United States of America, and which claims priority to European patent application number 12192974.9 filed 16 Nov. 2012. The entire contents of each patent application referenced above are hereby incorporated by reference.

REFERENCE TO A SEQUENCE LISTING

This application contains references to amino acid sequences and/or nucleic acid sequences which have been submitted concurrently herewith as the sequence listing text file 62095355_1.TXT file size 34 KiloBytes (KB), created on 1 Nov. 2017. The aforementioned sequence listing is hereby incorporated by reference in its entirety pursuant to 37 C.F.R. § 1.52(e)(5).

FIELD OF THE INVENTION

The invention relates to novel markers for diagnosing Alzheimer's disease.

BACKGROUND OF THE INVENTION

Very recently, molecular diagnostics has increasingly gained in importance. It has found an entry into the clinical diagnosis of diseases (inter alia detection of infectious pathogens, detection of mutations of the genome, detection of diseased cells and identification of risk factors for predisposition to a disease).

In particular, through the determination of gene expression in tissues, nucleic acid analysis opens up very promising new possibilities in the study and diagnosis of disease.

Nucleic acids of interest to be detected include genomic DNA, expressed mRNA and other RNAs such as MicroRNAs (abbreviated miRNAs). MiRNAs are a new class of small RNAs with various biological functions (A. Keller et al., Nat Methods. 2011 8(10):841-3). They are short (average of 20-24 nucleotide) ribonucleic acid (RNA) molecules found in eukaryotic cells. Several hundred different species of microRNAs (i.e. several hundred different sequences) have been identified in mammals. They are important for post-transcriptional gene-regulation and bind to complementary sequences on target messenger RNA transcripts (mRNAs), which can lead to translational repression or target degradation and gene silencing. As such they can also be used as biologic markers for research, diagnosis and therapy purposes.

Alzheimer's disease (AD), also known in medical literature as Alzheimer disease, is the most common form of dementia. Alzheimer's disease is characterised by loss of neurons and synapses in the cerebral cortex and certain subcortical regions and leads to a gross degeneration in these regions. In AD protein misfolding and aggregation (formation of so-called “plaques”) in the brain is caused by accumulation of abnormally folded A-beta and tau proteins in the affected tissues.

Early symptoms are often mistaken to be age-related problems. In the early stages, the most common symptom is difficulty in remembering recent events. When AD is suspected, the diagnosis is usually confirmed with functional tests that evaluate behaviour and cognitive abilities, often followed by imaging analysis of the brain. Imaging methods used for this purpose include computed tomography (CT), magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), and positron emission tomography (PET). In a patients already having dementia, SPECT appears to be superior in differentiating Alzheimer's disease from other possible causes, compared with the usual attempts employing mental testing and medical history analysis. A new technique known as PiB PET has been developed for directly and clearly imaging beta-amyloid deposits in vivo using a tracer that binds selectively to the beta-amyloid deposits. Beta-amyloid deposits. Recently, a miRNA diagnostic test from serum has been proposed (Geekiyanage et al., Exp Neurol. 2012 June; 235(2):491-6.)

Symptoms can be similar to other neurological disorders. Diagnosis can be time consuming, expensive and difficult. In particular, the reliable and early diagnosis of Alzheimer based on non-invasive molecular biomarkers remains a challenge. Till today, early diagnosis of AD remains a great challenge. So far, findings of an autopsy or biopsy represent the most reliable diagnostics for this common disease

The attempt to report the presence of beta-amyloid not only in the brain, but also in other tissues, e.g. the skin, showed only limited relevance for diagnosing AD. (Malaplate-Armand C, Desbene C, Pillot T, Olivier J L. Diagnostic biologique de la maladie d'Alzheimer: avancées, limites et perspectives. Rev Neurol 2009; 165:511-520). Thus, in the recent past, different imaging as well as in vitro diagnostic markers have been proposed in order to improve the AD diagnosis. Most importantly, biomarkers that can detect AD in pre-clinical stages are in the focus, however, such markers can so far be only reliably detected in cerebrospinal fluid (CSF). One prominent example is the combination of beta-amyloid-1-42 and tau. In addition, molecular genetics analyses of single nucleotide polymorphisms (SNPs) in the DNA of patients have been proposed to provide a risk estimation of the presence of AD. In addition to variants in genes, several studies have described an association between AD and genetic variation of mitochondrial DNA (mtDNA). Here, no consistent evidence for the relation of mtDNA variants and AD could be reported Hudson G, Sims R, Harold D, et al.; GERAD1 Consortium. No consistent evidence for association between mtDNA variants and Alzheimer disease. Neurology 2012; 78:1038-1042. However, although the heritability of AD is comparably high (60-80%), epigenetic and persistent factors also may play an important role.

Therefore, there exists an unmet need for an efficient, simple, reliable diagnostic test for AD.

OBJECT OF THE INVENTION

The technical problem underlying the present invention is to provide biological markers allowing to diagnose, screen for or monitor Alzheimer's disease, predict the risk of developing Alzheimer's disease, or predict an outcome of Alzheimer's disease.

SUMMARY OF THE INVENTION

Before the invention is described in detail, it is to be understood that this invention is not limited to the particular component parts of the process steps of the methods described as such methods may vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting. It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include singular and/or plural referents unless the context clearly dictates otherwise. It is also to be understood that plural forms include singular and/or plural referents unless the context clearly dictates otherwise. It is moreover to be understood that, in case parameter ranges are given which are delimited by numeric values, the ranges are deemed to include these limitation values.

In its most general terms, the invention relates to a collection of miRNA markers useful for the diagnosis, prognosis and prediction of Alzheimer's Disease.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the distribution of reads obtained by high throughput sequencing. The left pie chart shows that 95% of known miRNAs belong to one miRNA while all other 1.000 detected known markers make up only 5%. The novel detected miRNAs on the right hand side are much less abundant than the most frequently detected miRNA.

FIG. 2 shows the ROC curve for the most up-regulated miRNA, gene expression data obtained by NGS. X-axis: specificity, y-axis: sensitivity.

FIG. 3 shows the ROC curve for the most down-regulated miRNA, gene expression data obtained by NGS. X-axis: specificity, y-axis: sensitivity.

FIG. 4 shows increased performance by using marker combinations. The x-axis shows the number of miRNAs, the y axis shows the classification of performance, gene expression data obtained by NGS (solid line: sensitivity, broken line: accuracy, broken and dotted line: specificity).

FIG. 5 shows a combined score of AD, MCI and controls for the 7-marker signature brain-mir-112, hsa-miR-5010-3p, hsa-miR-103a-3p, hsa-miR-107, hsa-let-7d-3p, hsa-miR-532-5p, and brain-mir-161. The combined score (y-axis) was obtained using high throughput sequencing.

FIG. 6 shows the ROC curve for the 7-marker signature of FIG. 5, gene expression data obtained by NGS.

FIG. 7 shows the qRT-PCR validation of selected miRNAs, the up-regulated miRNAs brain-mir-112, brain-mir-161, hsa-let-7d-3p, hsa-miR-5010-3p, hsa-miR-26b-3p, hsa-miR-26a-5p, hsa-miR-1285-5p, and hsa-miR-151a-3p as well as the down-regulated markers hsa-miR-103a-3p, hsa-miR-107, hsa-miR-532-5p, and hsa-let-7f-5p. X-axis: expression of AD samples vs. control determined by NGS, y-axis: expression of AD samples vs. control determined by qRT-PCR.

FIG. 8 shows the ROC curve for the best single miRNAs from the validation study, gene expression data obtained by qRT-PCR. X-axis: specificity, y-axis: sensitivity.

FIG. 9 shows the ROC curve for the 7-marker signature brain-mir-112, hsa-miR-5010-3p, hsa-miR-103a-3p, hsa-miR-107, hsa-let-7d-3p, hsa-miR-532-5p, and brain-mir-161, qRT-PCR. X-axis: specificity, y-axis: sensitivity.

FIG. 10 shows the improved combined score of controls (left column) vs. AD patients (right column).

FIG. 11 shows the validation of 12 miRNAs in 7 diseases (AD, MCI, PD, DEP, CIS, SCH, and BD and controls). The 12 miRNAs are (denoted by columns 1-12, respectively) hsa-let-7f-5p, hsa-miR-1285-5p, hsa-miR-107, hsa-miR-103a-3p, hsa-miR-26b-3p, hsa-miR-26a-5p, hsa-miR-532-5p, hsa-miR-151a-3p, brain-mir-161, hsa-let-7d-3p, brain-mir-112, and hsa-miR-5010-3p.

FIG. 12 shows the combined score of the 7-miRNA signature brain-mir-112, hsa-miR-5010-3p, hsa-miR-103a-3p, hsa-miR-107, hsa-let-7d-3p, hsa-miR-532-5p, and brain-mir-161 for all diseases. The combined score (y-axis) was obtained using quantitative RT PCR.

FIG. 13 shows a combined score of AD, MCI and controls for the 12-marker signature hsa-let-7f-5p, hsa-miR-1285-5p, hsa-miR-107, hsa-miR-103a-3p, hsa-miR-26b-3p, hsa-miR-26a-5p, hsa-miR-532-5p, hsa-miR-151a-3p, brain-mir-161, hsa-let-7d-3p, brain-mir-112, and hsa-miR-5010-3p. The combined score (y-axis) was obtained using high throughput sequencing.

FIG. 14 shows the ROC curve for the 12-marker signature of FIG. 13, gene expression data obtained by NGS. X-axis: specificity, y-axis: sensitivity.

FIG. 15 shows the ROC curve for the 12-marker signature of FIG. 13, gene expression data obtained by qRT-PCR. X-axis: specificity, y-axis: sensitivity.

FIG. 16 shows the combined score of the 12-miRNA signature hsa-let-7f-5p, hsa-miR-1285-5p, hsa-miR-107, hsa-miR-103a-3p, hsa-miR-26b-3p, hsa-miR-26a-5p, hsa-miR-532-5p, hsa-miR-151a-3p, brain-mir-161, hsa-let-7d-3p, brain-mir-112, and hsa-miR-5010-3p for all diseases. The combined score (y-axis) was obtained using quantitative RT PCR.

DETAILED DESCRIPTION OF THE INVENTION Definitions

Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

The term “predicting an outcome” of a disease, as used herein, is meant to include both a prediction of an outcome of a patient undergoing a given therapy and a prognosis of a patient who is not treated.

An “outcome” within the meaning of the present invention is a defined condition attained in the course of the disease. This disease outcome may e.g. be a clinical condition such as “relapse of disease”, “remission of disease”, “response to therapy”, a disease stage or grade or the like.

A “risk” is understood to be a probability of a subject or a patient to develop or arrive at a certain disease outcome. The term “risk” in the context of the present invention is not meant to carry any positive or negative connotation with regard to a patient's wellbeing but merely refers to a probability or likelihood of an occurrence or development of a given event or condition.

The term “clinical data” relates to the entirety of available data and information concerning the health status of a patient including, but not limited to, age, sex, weight, menopausal/hormonal status, etiopathology data, anamnesis data, data obtained by in vitro diagnostic methods such as blood or urine tests, data obtained by imaging methods, such as x-ray, computed tomography, MRI, PET, spect, ultrasound, electrophysiological data, genetic analysis, gene expression analysis, biopsy evaluation, intraoperative findings.

The term “classification of a sample” of a patient, as used herein, relates to the association of said sample with at least one of at least two categories. These categories may be for example “high risk” and “low risk”; or high, intermediate and low risk; wherein risk is the probability of a certain event occurring in a certain time period, e.g. occurrence of disease, progression of disease, etc. It can further mean a category of favourable or unfavourable clinical outcome of disease, responsiveness or non-responsiveness to a given treatment or the like. Classification may be performed by use of an algorithm, in particular a discriminate function. A simple example of an algorithm is classification according to a first quantitative parameter, e.g. expression level of a nucleic acid of interest, being above or below a certain threshold value. Classification of a sample of a patient may be used to predict an outcome of disease or the risk of developing a disease. Instead of using the expression level of a single nucleic acid of interest, a combined score of several nucleic acids of interest of interest may be used. Further, additional data may be used in combination with the first quantitative parameter. Such additional data may be clinical data from the patient, such as sex, age, weight of the patient, disease grading etc.

A “discriminant function” is a function of a set of variables used to classify an object or event. A discriminant function thus allows classification of a patient, sample or event into a category or a plurality of categories according to data or parameters available from said patient, sample or event. Such classification is a standard instrument of statistical analysis well known to the skilled person. E.g. a patient may be classified as “high risk” or “low risk”, “in need of treatment” or “not in need of treatment” or other categories according to data obtained from said patient, sample or event. Classification is not limited to “high vs. low”, but may be performed into a plurality of categories, grading or the like. Examples for discriminant functions which allow a classification include, but are not limited to discriminant functions defined by support vector machines (SVM), k-nearest neighbors (kNN), (naive) Bayes models, or piecewise defined functions such as, for example, in subgroup discovery, in decision trees, in logical analysis of data (LAD) an the like.

The term “expression level” refers, e.g., to a determined level of expression of a nucleic acid of interest. The term “pattern of expression levels” refers to a determined level of expression com-pared either to a reference nucleic acid, e.g. from a control, or to a computed average expression value, e.g. in DNA-chip analyses. A pattern is not limited to the comparison of two genes but is also related to multiple comparisons of genes to reference genes or samples. A certain “pattern of expression levels” may also result and be determined by comparison and measurement of several nucleic acids of interest disclosed hereafter and display the relative abundance of these transcripts to each other. Expression levels may also be assessed relative to expression in different tissues, patients versus healthy controls, etc.

A “reference pattern of expression levels”, within the meaning of the invention shall be understood as being any pattern of expression levels that can be used for the comparison to another pattern of expression levels. In a preferred embodiment of the invention, a reference pattern of expression levels is, e.g., an average pattern of expression levels observed in a group of healthy or diseased individuals, serving as a reference group.

In the context of the present invention a “sample” or a “biological sample” is a sample which is derived from or has been in contact with a biological organism. Examples for biological samples are: cells, tissue, body fluids, biopsy specimens, blood, urine, saliva, sputum, plasma, serum, cell culture supernatant, and others.

A “probe” is a molecule or substance capable of specifically binding or interacting with a specific biological molecule. The term “primer”, “primer pair” or “probe”, shall have ordinary meaning of these terms which is known to the person skilled in the art of molecular biology. In a preferred embodiment of the invention “primer”, “primer pair” and “probes” refer to oligonucleotide or polynucleotide molecules with a sequence identical to, complementary too, homologues of, or homologous to regions of the target molecule or target sequence which is to be detected or quantified, such that the primer, primer pair or probe can specifically bind to the target molecule, e.g. target nucleic acid, RNA, DNA, cDNA, gene, transcript, peptide, polypeptide, or protein to be detected or quantified. As understood herein, a primer may in itself function as a probe. A “probe” as understood herein may also comprise e.g. a combination of primer pair and internal labeled probe, as is common in many commercially available qPCR methods.

A “gene” is a set of segments of nucleic acid that contains the information necessary to produce a functional RNA product in a controlled manner. A “gene product” is a biological molecule produced through transcription or expression of a gene, e.g. an mRNA or the translated protein.

A “miRNA” is a short, naturally occurring RNA molecule and shall have the ordinary meaning understood by a person skilled in the art. A “molecule derived from an miRNA” is a molecule which is chemically or enzymatically obtained from an miRNA template, such as cDNA.

The term “array” refers to an arrangement of addressable locations on a device, e.g. a chip device. The number of locations can range from several to at least hundreds or thousands. Each location represents an independent reaction site. Arrays include, but are not limited to nucleic acid arrays, protein arrays and antibody-arrays. A “nucleic acid array” refers to an array containing nucleic acid probes, such as oligonucleotides, polynucleotides or larger portions of genes. The nucleic acid on the array is preferably single stranded. A “microarray” refers to a biochip or biological chip, i.e. an array of regions having a density of discrete regions with immobilized probes of at least about 100/cm2.

A “PCR-based method” refers to methods comprising a polymerase chain reaction PCR. This is a method of exponentially amplifying nucleic acids, e.g. DNA or RNA by enzymatic replication in vitro using one, two or more primers. For RNA amplification, a reverse transcription may be used as a first step. PCR-based methods comprise kinetic or quantitative PCR (qPCR) which is particularly suited for the analysis of expression levels). When it comes to the determination of expression levels, a PCR based method may for example be used to detect the presence of a given mRNA by (1) reverse transcription of the complete mRNA pool (the so called transcriptome) into cDNA with help of a reverse transcriptase enzyme, and (2) detecting the presence of a given cDNA with help of respective primers. This approach is commonly known as reverse transcriptase PCR (rtPCR). The term “PCR based method” comprises both end-point PCR applications as well as kinetic/real time PCR techniques applying special fluorophors or intercalating dyes which emit fluorescent signals as a function of amplified target and allow monitoring and quantification of the target. Quantification methods could be either absolute by external standard curves or relative to a comparative internal standard.

The term “next generation sequencing” or “high throughput sequencing” refers to high-throughput sequencing technologies that parallelize the sequencing process, producing thousands or millions of sequences at once. Examples include Massively Parallel Signature Sequencing (MPSS) Polony sequencing, 454 pyrosequencing, Illumina (Solexa) sequencing, SOLiD sequencing, Ion semiconductor sequencing, DNA nanoball sequencing, Helioscope™ single molecule sequencing, Single Molecule SMR™ sequencing, Single Molecule real time (RNAP) sequencing, Nanopore DNA sequencing.

The term “marker” or “biomarker” refers to a biological molecule, e.g., a nucleic acid, peptide, protein, hormone, etc., whose presence or concentration can be detected and correlated with a known condition, such as a disease state, or with a clinical outcome, such as response to a treatment.

In particular, the invention relates to a method of classifying a sample of a patient suffering from or at risk of developing Alzheimer's Disease, wherein said sample is a blood sample, said method comprising the steps of:

a) determining in said sample an expression level of at least one miRNA selected from the group consisting of miRNAs having the sequence SEQ ID NO 59, SEQ ID NO 65, SEQ ID NO 1 to SEQ ID NO 58, SEQ ID NO 60 to SEQ ID NO 64 and SEQ ID NO 66 to SEQ ID NO 170, b) comparing the pattern of expression level(s) determined in step a) with one or several reference pattern(s) of expression levels; and c) classifying the sample of said patient from the outcome of the comparison in step b) into one of at least two classes.

A reference pattern of expression levels may, for example, be obtained by determining in at least one healthy subject the expression level of at least one miRNA selected from the group consisting of miRNAs having the sequence SEQ ID NO 59, SEQ ID NO 65, SEQ ID NO 1 to SEQ ID NO 58, SEQ ID NO 60 to SEQ ID NO 64 and SEQ ID NO 66 to SEQ ID NO 170.

It is within the scope of the invention to assign a numerical value to an expression level of the at least one miRNA determined in step a).

It is further within the scope of the invention to mathematically combine expression level values to obtain a pattern of expression levels in step (b), e.g. by applying an algorithm to obtain a normalized expression level relative to a reference pattern of expression level(s).

In a further aspect the invention relates to a method for diagnosing Alzheimer's Disease, predicting risk of developing Alzheimer's Disease, or predicting an outcome of Alzheimer's Disease in a patient suffering from or at risk of developing Alzheimer's Disease, said method comprising the steps of:

a) determining in a blood sample from said patient, the expression level of at least one miRNA selected from the group consisting of miRNAs with the sequence SEQ ID NO 59, SEQ ID NO 65, SEQ ID NO 1 to SEQ ID NO 58, SEQ ID NO 60 to SEQ ID NO 64 and SEQ ID NO 66 to SEQ ID NO 170, b) comparing the pattern of expression level(s) determined in step a) with one or several reference pattern(s) of expression levels; and c) diagnosing Alzheimer's Disease, predicting a risk of developing Alzheimer's Disease, or predicting an outcome of Alzheimer's Disease from the outcome of the comparison in step b).

According to an aspect of the invention, said at least one miRNA is selected from the group consisting of miRNAs with the sequence SEQ ID NO 59, SEQ ID NO 65, SEQ ID NO 1 and SEQ ID NO 56.

According to an aspect of the invention, step a) comprises determining the expression level of the miRNAs: brain-mir-112, hsa-miR-5010-3p, hsa-miR-103a-3p, hsa-miR-107, hsa-let-7d-3p, hsa-miR-532-5p, and brain-mir-161.

According to an aspect of the invention, step a) comprises in step a) determining the expression level of 5 miRNAs selected from the signatures consisting of

brain-mir-112 hsa-miR-5010-3p hsa-miR-1285-5p hsa-miR-151a-3p hsa-let-7f-5p, hsa-miR-3127-3p hsa-miR-1285-5p hsa-miR-425-5p hsa-miR- 148b-5p hsa-miR-144-5p, hsa-miR-3127-3p hsa-miR-3157-3p hsa-miR-148b-5p hsa-miR-151a-3p hsa-miR-144-5p, hsa-miR-3127-3p hsa-miR-1285-5p hsa-miR-425-5p hsa-miR- 151a-3p hsa-miR-144-5p, hsa-miR-1285-5p brain-mir-112 hsa-miR-5010-3p hsa-miR- 151a-3p hsa-let-7a-5p, hsa-miR-5001-3p hsa-miR-1285-5p hsa-miR-425-5p hsa-miR- 148b-5p hsa-miR-144-5p, hsa-miR-3127-3p hsa-miR-1285-5p hsa-miR-148b-5p hsa-miR-151a-3p hsa-miR-144-5p, hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-425-5p hsa-miR- 148b-5p hsa-miR-144-5p, hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-151a-3p hsa-miR-144-5p hsa-let-7a-5p, hsa-miR-1285-5p brain-mir-112 hsa-miR-425-5p hsa-miR-151a- 3p hsa-miR-144-5p, hsa-miR-5001-3p hsa-miR-1285-5p brain-mir-112 hsa-miR- 151a-3p hsa-let-7f-5p, hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-148b-5p hsa-miR-144-5p hsa-let-7f-5p, hsa-miR-1285-5p hsa-miR-3157-3p hsa-miR-148b-5p hsa-miR-151a-3p hsa-miR-144-5p, hsa-miR-5001-3p hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-151a-3p hsa-let-7f-5p, brain-mir-431 hsa-miR-1285-5p hsa-miR-3157-3p hsa-miR-151a-3p hsa-miR-144-5p, hsa-miR-3127-3p hsa-miR-1285-5p brain-mir-112 hsa-miR- 425-5p hsa-miR-151a-3p, hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-151a-3p hsa-miR-144-5p hsa-let-7f-5p, hsa-miR-550a-5p hsa-miR-1285-5p brain-mir-112 hsa-miR- 151a-3p hsa-let-7f-5p, hsa-miR-1285-5p brain-mir-112 hsa-miR-148b-5p hsa-miR- 151a-3p hsa-miR-144-5p, and hsa-miR-5001-3p brain-mir-112 hsa-miR-5010-3p hsa-miR- 151a-3p hsa-let-7f-5p.

According to an aspect of the invention, the expression levels of a plurality of miRNAs are determined as expression level values and step (b) comprises mathematically combining the expression level values of said plurality of miRNAs.

It is within the scope of the invention to apply an algorithm to the numerical value of the expression level of the at least one miRNA determined in step a) to obtain a disease score to allow classification of the sample or diagnosis, prognosis or prediction of the risk of developing Alzheimer's Disease, or prediction of an outcome of Alzheimer's Disease. A non-limiting example of such an algorithm is to compare the numerical value of the expression level against a threshold value in order to classify the result into one of two categories, such as high risk/low risk, diseased/healthy or the like. A further non-limiting example of such an algorithm is to combine a plurality of numerical values of expression levels, e.g. by summation, to obtain a combined score. Individual summands may be normalized or weighted by multiplication with factors or numerical values representing the expression level of an miRNA, numerical values representing clinical data, or other factors.

It is within the scope of the invention to apply a discriminant function to classify a result, diagnose disease, predict an outcome or a risk.

According to an aspect of the invention, the expression level in step (a) is obtained by use of a method selected from the group consisting of a Sequencing-based method, an array based method and a PCR-based method.

According to an aspect of the invention, the expression levels of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 miRNAs are determined to obtain a pattern of expression levels.

According to an aspect of the invention, step a) comprises in step a) determining the expression level of the miRNAs: hsa-let-7f-5p, hsa-miR-1285-5p, hsa-miR-107, hsa-miR-103a-3p, hsa-miR-26b-3p, hsa-miR-26a-5p, hsa-miR-532-5p, hsa-miR-151a-3p, brain-mir-161, hsa-let-7d-3p, brain-mir-112, and hsa-miR-5010-3p.

The invention further relates to a kit for performing the methods of the invention, said kit comprising means for determining in said blood sample from said patient, an expression level of at least one miRNA selected from the group consisting of miRNAs with the sequence SEQ ID NO 59, SEQ ID NO 65, SEQ ID NO 1 to SEQ ID NO 58, SEQ ID NO 60 to SEQ ID NO 64 and SEQ ID NO 66 to SEQ ID NO 170.

The means for determining the expression level of said at least one miRNA may comprise an oligonucleotide probe for detecting or amplifying said at least one miRNA, means for determining the expression level based on an array-based method, a PCR-based method, a sequencing-based method or any other suitable means for determining the expression level.

According to an aspect of the invention, the kit further comprises at least one reference pattern of expression levels for comparing with the expression level of the at least one miRNA from said sample. The reference pattern of expression may include at least one digital or numerical information and may be provided in any readable or electronically readable form, including, but not limited to printed form, electronically stored form on a computer readable medium, such as CD, smart card, or provided in downloadable form, e.g. in a computer network such as the internet.

The invention further relates to computer program product useful for performing the methods of the invention, comprising

-   -   means for receiving data representing an expression level of at         least one miRNA in a patient blood sample selected from the         group consisting of miRNAs with the sequence SEQ ID NO 59, SEQ         ID NO 65, SEQ ID NO 1 to SEQ ID NO 58, SEQ ID NO 60 to SEQ ID NO         64 and SEQ ID NO 66 to SEQ ID NO 170,     -   means for receiving data representing at least one reference         pattern of expression levels for comparing with the expression         level of the at least one miRNA from said sample,     -   means for comparing said data representing the expression level         of the at least one miRNA in a patient sample, and     -   optionally means for determining a diagnosis of Alzheimer's         Disease, a prediction of a risk of developing Alzheimer's         Disease, or a prediction of an outcome of Alzheimer's Disease         from the outcome of the comparison in step b).

The computer program product may be provided on a storable electronic medium, such as a solid state memory, disk, CD or other. It may be stored locally on a computer. It may be implemented as network-based program or application, including a web- or internet-based application. It may be implemented in a diagnostic device, such as an analyzer instrument. It may be operably connected to a device for outputting information, such as a display, printer or the like.

EXAMPLES

Additional details, features, characteristics and advantages of the object of the invention are further disclosed in the following description and figures of the respective examples, which, in an exemplary fashion, show preferred embodiments of the present invention. However, these examples should by no means be understood as to limit the scope of the invention.

The invention relates to methods for diagnosing Alheimer's Disease with miRNA markers.

Diagnosis of Alzheimer's Disease can be challenging in patients presenting with generally age-related syndromes such as forgetfulness. In particular, it is difficult to diagnose the earliest stages of disease. However, it would be particularly desirable to have a reliable diagnostic test for this stage of disease, as the chance of therapeutic and social intervention is better during this early disease stage.

Here, the abundance of miRNAs in blood samples of Alzheimer's Disease patients has been compared in an unbiased approach against healthy controls and patients suffering from other neuronal disorders. This approach involved a massive effort of sequencing miRNAs from samples and thus was open to the discovery of novel markers not yet described in the prior art. Further, the use of blood samples as a source of expression information of miRNA markers has several tangible advances which are not available in other sample sources such as serum or tissue, such as ease of sample procurement and handling, sample preparation, and robustness and consistency of expression patterns.

Materials and Methods

Patient Cohorts

The expression of miRNAs in peripheral blood of a total of 219 patients and healthy controls was determined, either by NGS or by qRT-PCR or both. Blood was obtained from patients with Alzheimer's Disease (AD) (n=106), patients with Mild Cognitive Impairement (MCI) (n=21), patients with Multiple Sclerosis (Clinically Isolated Syndrome, CIS) (n=17), patients with Parkinson's Disease (PD) (n=9), patients with Mild Depression (DEP) (n=15), Bipolar Disorder (BD) (n=15), Schizophrenia (Schiz) (n=14), and from healthy controls (n=22).

First, samples from AD patients (n=48), MCI patients (n=20) and healthy controls (n=22) were analyzed by Next-generation sequencing. For validation purposes the expression of single miRNAs was analyzed using qRT-PCR in the same samples as used for NGS, if enough RNA was available. The number of samples was further expanded by further samples from patients with AD, CIS, PD, DEP, BD, and Schiz, resulting in a total of 205 samples analyzed by qRT-PCR. In detail, a total of 95 samples from AD patients, 19 samples from MCI patients, 17 samples from CIS patients, 9 samples from PD patients, 15 samples from DEP patients, 15 samples from BD patients, 14 samples from Schiz patients, and 21 samples from healthy controls were analyzed.

RNA Isolation

Total RNA including miRNA was isolated using the PAXgene Blood miRNA Kit (Qiagen) following the manufacturer's recommendations. Isolated RNA was stored at −80° C. RNA integrity was analyzed using Bioanalyzer 2100 (Agilent) and concentration and purity were measured using NanoDrop 2000 (Thermo Scientific). A total of four samples (three controls and one RRMS) failed the quality criteria and were excluded from the study.

Library Preparation and Next-Generation Sequencing

For the library preparation, 200 ng of total RNA was used per sample, as determined with a RNA 6000 Nano Chip on the Bioanalyzer 2100 (Agilent). Preparation was performed following the protocol of the TruSeq Small RNA Sample Prep Kit (Illumina). Concentration of the ready prepped libraries was measured on the Bioanalyzer using the DNA 1000 Chip. Libraries were then pooled in batches of six samples in equal amounts and clustered with a concentration of 9 pmol in one lane each of a single read flowcell using the cBot (Illumina). Sequencing of 50 cycles was performed on a HiSeq 2000 (Illumina). Demultiplexing of the raw sequencing data and generation of the fastq files was done using CASAVA v.1.8.2.

NGS Data Analysis

The raw illumina reads were first preprocessed by cutting the 3′ adapter sequence using the programm fastx_clipper from the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/). Reads shorter than 18 nts after clipping were removed. The remaining reads are reduced to unique reads and their frequency per sample to make the mapping steps more time efficient. For the remaining steps, we used the miRDeep2 pipeline. These steps consist of mapping the reads against the genome (hg19), mapping the reads against miRNA precursor sequences from mirbase release v18, summarizing the counts for the samples, and the prediction of novel miRNAs. Since the miRDeep2 pipeline predicts novel miRNAs per sample, the miRNAs were merged afterwards as follows: first, the novel miRNAs per sample that have a signal-to-noise ratio of more than 10 were extracted. Subsequently, only those novel miRNAs that are located on the same chromosome were merged, and both their mature forms share an overlap of at least 11 nucleotides.

Quantitative Real Time-PCR (qRT-PCR)

Out of the NGS results 7 miRNAs were selected that were deregulated in both, the comparison between patients with Alzheimer's Disease and patients with Mild Cognitive Impairment, and the comparison between patients with Alzheimer's Disease and healthy individuals. Five of the seven miRNAs, namely hsa-miR-5010-3p, hsa-miR-103a-3p, hsa-miR-107, hsa-let-7d-3p, and hsa-miR-532-5p were already known mature miRNAs included in miRBase, two miRNAs, namely brain-mir-112 and brain-mir-161, were newly identified and not yet included in miRBase. As endogenous control the small nuclear RNA RNU48 as used.

The miScript PCR System (Qiagen) was used for reverse transcription and qRT-PCR. A total of 200 ng RNA was converted into cDNA using the miScript Reverse Transcription Kit according to the manufacturers' protocol. For each RNA we additionally prepared 5 μl reactions containing 200 ng RNA and 4 μl of the 5× miScript RT Buffer but no miScript Reverse Transcriptase Mix, as negative control for the reverse transcription (RT− control). The qRT-PCR was performed with the miScript SYBR® Green PCR Kit in a total volume of 20 μl per reaction containing 1 μl cDNA according to the manufacturers' protocol. For each miScript Primer Assay we additionally prepared a PCR negative-control with water instead of cDNA (non-template control, NTC).

Bioinformatics Analysis

First the read counts were normalized using standard quantile normalization. All miRNAs with less than 50 read counts were excluded from further considerations. Next, we calculated for each miRNA the area under the receiver operator characteristic curve (AUC), the fold-change, and the significance value (p-value) using t-tests. All significance values were adjusted for multiple testing using the Benjamini Hochberg approach. The bioinformatics analyses have been carried out using the freely available tool. R. Furthermore, we carried out a miRNA enrichment analysis using the TAM tool (http://202.38.126.151/hmdd/tools/tam.html).

Computing Combined Scores

Briefly, to compute a combined expression score for n up-regulated markers and m down-regulated markers the difference d between the expression value x_((a)) of a patient a and the average expression value of all controls μ is determined. For down-regulated markers, the difference can be multiplied by (−1), thus yielding a positive value. The differences for n markers can be added up to yield a combined score Z, such that Z _((a)) =Σd _((1-n))(upregulated)+Σ(−1)d _((1-m))(down-regulated) Wherein d=x _((a))−μ

To make combined scores between different marker scores comparable (e.g. to compare a (n+m)=7 marker score against a (n+m)=12 marker score, the combined score can be divided by (n+m): Zcomp=1/(n+m)(Σd _((1-n))(upregulated)+Σ(−1)d _((1-m))(down-regulated))

Other factors can be applied to the individual summands d of the combined score or the combined score Z as a whole.

Results

Screening Using High-Throughput Sequencing

To detect potential Alzheimer biomarkers a high-throughput sequencing of n=22 controls samples (C), n=48 Alzheimer patient (AD) samples and n=20 Mild Cognitive Impairment (MCI) samples was carried out. Precisely, Illumina HiSeq 2000 sequencing and multiplexed 8 samples on each sequencing lane was carried out. Thereby, 1150 of all human mature miRNAs in at least a single sample could be detected.

TABLE 1 Patient Cohorts Cohort Size Cohort Size Disease Screening Replication Controls 22 21 Alzheimer 48 86 (US) Alzheimer 0 9 (GER) Parkinson 0 9 Disease Mild 20 18 Cognitive Impairment Schizophrenia 0 14 Bipolar 0 15 disease Multiple 0 17 Sclerosis (CIS) Depression 0 15 SUM 90 204

The most abundant miRNAs were hsa-miR-486-5p with an average read-count of 13,886,676 and a total of 1.2 billion reads mapping to this miRNA, hsa-miR-92a-3p with an average of 575,359 reads and a total of 52 million reads mapping to this miRNA and miR-451a with an average of 135,012 reads and a total of 12 million reads mapping to this miRNA. The distribution of reads mapping to the three most abundant and all other miRNAs is shown in FIG. 1 (left pie chart). Additionally, 548 novel mature miRNA candidates were detected that have been previously not present in the Sanger miRBase. These miRNA candidates have generally however been much less abundant as compared to the known human miRNAs. The most abundant one, denoted as brain-miR-314 was detected on average with 3,587 reads per sample and a total of 322,868 reads. Second highest expressed miRNA, brain-miR-247 was present on average with 3,112 and with a total of 280,115 reads, third most abundant miRNA brain-miR-12 at an average of 2,630 and a total of 236,728 reads. In the list of all, novel and known miRNAs, brain-miR-314 would be ranked on position 37, i.e., 36 known human miRNAs were more abundant than the highest abundant novel one. While a total of 1.4 Bn reads mapped to the known miRNAs, only 2.3 Mn mapped to the novel miRNA candidates. This relation shows that a very high sequencing capacity is required to reach the sensitivity in order to detect rare variants of novel miRNAs in human blood samples. Interestingly, as the right pie chart in FIG. 1 denotes, the candidate miRNAs are much more equally distributed as compared to the known ones, where the most abundant miRNA was responsible for 91% of all reads.

To detect potential biomarker candidates two-tailed t-tests and adjusted the significance values for multiple testing using Benjamini Hochberg adjustment were computed. All markers with adjusted significance values below 0.05 were considered statistically significant. Additionally, the area under the receiver operator characteristics curve (AUC) was computed to understand the specificity and sensitivity of miRNAs for Alzheimer diagnosis. Altogether, 170 significantly dys-regulated miRNAs we detected, 55 markers were significantly down-regulated in Alzheimer, while 115 were significantly up-regulated. A list of the respective 170 markers is presented in Supplemental Table 1 a and b. These 170 miRNA markers have the corresponding sequences SEQ ID NO 1 to SEQ ID NO 170 in the attached sequence protocol.

A list of all miRNA molecules described herein is given in Supplemental Table 4 containing an overview of the miRNA markers, including sequence information.

It is noted that the mature miRNa originate from miRNA precursor molecules of length of around 120 bases. Several examples exists where the miRNA precursors vary from each other while the subset of the around 20 bases belonging to the mature miRNA are identical. Thus, novel mature miRNAs can have the same sequence but different SEQ ID NO identifiers.

MiRNA markers are denoted by their common name (e.g. has-miR-144-5p or hsa-let 7f-5p) and are searchable in publically available databases. In this invention there are also described novel miRNA markers which have been named with names beginning with the prefix “brain-miR”. They are listed in supplemental table 2 with their sequence and their SEQ ID NO according to the sequence protocol.

The ROC curves for the most up-regulated marker (hsa-miR-30d-5p with p-value of 8*10⁻⁹) as well as the most down-regulated marker (hsa-miR-144-5p with p-value of 1.5*10⁻⁵) are presented in FIGS. 2 and 3, where the high AUC value indicates that already one single miRNA might have sufficient power to differentiate between cases and controls. Both miRNAs have however already been describe with many other human pathologies including different neoplasms and thus are non-specific for AD. Remarkably, the set of significant biomarkers also contained also 58 miRNAs that had so far not been reported, which have been designated with miRNA Names beginning with. Of these, only 10 were down-regulated while the majority of 48 miRNAs was highly up-regulated in AD.

To understand whether the detected biomarkers are also dys-regulated in MCI patients t-tests and AUC values for the comparison of healthy controls versus MCI were likewise computed. Here, ten markers remained statistically significant following adjustment for multiple testing. Of these, 8 were down-while 2 were up-regulated in MCI patients. Notably, 9 of them have been likewise significantly dys-regulated in MCI patients, namely hsa-miR-29c-3p, hsa-miR-29a-3p, hsa-let-7e-5p, hsa-let-7a-5p, hsa-let-7f-5p, hsa-miR-29b-3p, hsa-miR-98, hsa-miR-425-5p and hsa-miR-181a-2-3p. Only miRNA hsa-miR-223-3p was just significant in MCI patients while not in AD patients. A full list of all MCI biomarkers, identified as SEQ ID NO 171-235 in the attached sequence listing is presented in Supplemental Table 3. It is noted that mature miRNA originate from miRNA precursor molecules of length of around 120 bases. Several examples exists where the miRNA precursors vary from each other while the subset of the around 20 bases belonging to the mature miRNA are identical. Thus, novel mature miRNAs can have the same sequence but different identifiers.

Besides single markers, combinations of multiple markers have demonstrated a potential to improve the diagnostic accuracy. To test this hypothesis, a standard machine learning approach was applied. In a cross-validation loop, the markers with lowest significance values were stepwise added and repeatedly radial basis function support vector machines were carried out. The accuracy, specificity and sensitivity depend on the number of biomarkers are presented in FIG. 4. As shown there, accuracy, specificity and sensitivity increase up to a signature number of 250 miRNAs and then converge to 90%. However, this set of miRNAs contains a significant amount of redundant biomarkers, i.e., markers that have almost identical information content to each other and are highly correlated such that even significantly smaller sets of markers can be expected to perform highly accurate distinction in Alzheimer samples and controls. We selected a signature of just 7 markers, namely the up-regulated miRNAs brain-mir-112, brain-mir-161, hsa-let-7d-3p and hsa-miR-5010-3p as well as the down-regulated markers hsa-miR-103a-3p, hsa-miR-107 and hsa-miR-532-5p. To combine the values of the 7 miRNAs in one score we calculated the average z-score as detailed in the Material & Methods section. While we reached averaged values of 0.087 and standard deviation of 0.72 for the controls and average values of 0.22 and standard deviation of 0.74 for the MCI patients, AD patients reached a much higher score of 0.63 at a standard deviation of 0.64. Thus, the Alzheimer patients have significantly higher scores as controls, indicated by the two-tailed t-test p-value of 0.025. These numbers are detailed as bar-chart in FIG. 5. The ROC curve for the signature showing an AUC of 84.3% with 95% CI of 75.3%-93.2% is presented in FIG. 6.

A further signature of 12 markers with limited cross-correlation was selected, including the most strongly dys-regulated markers that are less frequently dys-regulated in other diseases and show a potential to separate AD also from MCI. More precisely, this selected signature contains the up-regulated miRNAs brain-mir-112, brain-mir-161, hsa-let-7d-3p, hsa-miR-5010-3p, hsa-miR-26b-3p, hsa-miR-26a-5p, hsa-miR-1285-5p, and hsa-miR-151a-3p as well as the down-regulated markers hsa-miR-103a-3p, hsa-miR-107, hsa-miR-532-5p, and hsa-let-7f-5p. To combine the values of the 12 miRNAs in one score the combined score was computed as discussed above. While averaged values of 0 and standard deviation of 0.39 for the controls were reached and average values of 0.32 and standard deviation of 0.5 for the MCI patients were reached, AD patients reached a much higher score of 0.93 at a standard deviation of 0.54. Thus, the Alzheimer patients have significantly higher scores as controls, indicated by the two-tailed t-test p-value of 3.7*10⁻¹¹ in case of AD versus C as well as 6*10⁻⁵ in case of AD versus MCI. In addition we computed the same scores for a set of 15 MS samples, showing a likewise decreased score of 0.1 at standard deviation of 0.34.

Biological Relevance of miRNAs for AD

To understand the biological function of the dys-regulated miRNAs better a miRNA enrichment analysis for the up- and down-regulated miRNAs was applied (Ming Lu, Bing Shi, Juan Wang, Qun Cao and Qinghua Cui. TAM: A method for enrichment and depletion analysis of a microRNA category in a list of microRNAs. BMC Bioinformatics 2010, 11:419 (9 Aug. 2010). The results of this analysis are detailed in Table 2. Altogether, for the 55 down-regulated miRNAs 11 significant categories after adjustment for multiple testing were detected while for the 115 up-regulated just a single category remained significant, the miR-30 family with 5 members being up-regulated. In contrast, for the down-regulated miRNAs 7 miRNAs of the let-7 family were found being significant. In addition, the set contained also 8 miRNAs belonging to anti-cell proliferation and 13 tumor suppressors. Finally, we were able to show that the down-regulated miRNAs correlate to 8 diseases, including Alzheimer. Here, we found 5 miRNAs being relevant, including hsa-miR-17, hsa-miR-29a, hsa-miR-29b, hsa-miR-106b and hsa-miR-107.

TABLE 2 Regulated Pathways and categories down up Term Count p-value Count p-value anti-cell proliferation 8 4.60-3 n.s. n.s. miRNA tumor suppressors 13 6.71-3 n.s. n.s. let-7 family 7 7.00-3 n.s. n.s. Digestive System 6 0.0144 n.s. n.s. Neoplasms Pituitary Neoplasms 7 0.0168 n.s. n.s. Lymphoma, Primary 7 0.0201 n.s. n.s. Effusion Sarcoma, Kaposi 7 0.021 n.s. n.s. Carcinoma, Non-Small Cell 6 0.027 n.s. n.s. Lung Neoplasms 14 0.028 n.s. n.s. Colonic Neoplasms 12 0.0388 n.s. n.s. Alzheimer Disease 5 0.0433 n.s. n.s. mir-30 family n.s. n.s. 5 8.95-3 Validation of Signature by q-RT-PCR

In order to transfer the signature to clinical routine settings it is essential that the proposed in-vitro diagnostic test can be applied in molecular diagnostic labs in reasonable time using standard equipment. To this end, qRT-PCR represents a suitable solution to replicate and validate our AD signature using this approach. In addition to measure just controls, AD and MCI patients, a wide range of other neurological disorders were also included. For AD, besides the US cohort also a set of samples collected in Germany were included. The full overview on measured samples is provided in Table 1.

First, the fold quotients of the initial screening cohort were compared and analyzed by next-generation sequencing and this was compared to the performance of the same miRNAs by qRT-PCR. As the scatter-plot in FIG. 7 presents, all miRNAs have been dys-regulated in the same direction by both approaches and in both cohorts, indicating a very high degree of concordance between screening and validation study. As for the next generation sequencing screening approach AUC values were calculated for the validation qRT-PCR cohort. The best single miRNA was miR-5010-3p with an AUC of 84.5% (AUC of screening: 75.5%). On average, the 7 miRNAs reached an AUC value of 71%, indicating the high diagnostic information content. Next, the question was addressed whether the combination of the 7 miRNAs can further improve the diagnosis of AD. The same z-scored based approach was applied.

While averaged values of 0.087 and standard deviation of 0.72 for the controls and average values of 0.22 and standard deviation of 0.74 were reached for the MCI patients, AD patients reached a much higher score of 0.63 at a standard deviation of 0.64.

For controls an average value of 0 (screening: −0.087) at a standard deviation of 0.34 (screening: 0.72) was obtained, while for AD patients, the score was as high as 0.7 (screening 0.63) at standard deviation of 0.45 (screening: 0.64). Thus, AD patients have significantly higher values as compared to controls since the 2-tailed t-test p-value is as low as 1.3*10-9 (screening 0.025). The z-scores are presented as bar-diagram in FIG. 10. Here, it can be clearly seen that especially the standard deviations are much smaller for the qRT-PCR based validation cohort.

Scores of Other Neurological Disorders

Next the question was asked whether a cohort of other neurological disorders shows likewise significant deviations to controls. As detailed in Table 1 we measured a second cohort of Alzheimer patients, Parkinson disease, mild cognitive impairment, schizophrenia, bipolar disorder, multiple sclerosis (CIS) depression patients for the signature of 7 miRNAs. In FIG. 11, the bar diagrams for all diseases and all miRNAs are present. Here, the Alzheimer patients score is set to 0, as described earlier we have four down- and three up-regulated miRNAs for the controls. For mild cognitive impairment patients the same four miRNAs were down- and the same three miRNAs were up-regulated, providing strong evidence that the MCI signature is much closer to controls as compared to AD. For CIS patients only two miRNAs were down-regulated, while the third one was not dys-regulated and the remaining three were strongly up-regulated. For Parkinson disease, the first 5 miRNAs were down-while the remaining two were strongly up-regulated. For Schizophrenia and Bipolar Disease, almost all miRNAs were strongly up-regulated, in contrast, for Depression all miRNAs were significantly down-regulated. In summary, the results promise that AD can not only be distinguished from controls but also very well from other neurological disorders. Of course the same z-score based approach can be applied as for the Alzheimer and control patients in order to get an overall score for each cohort.

Further significant signatures of miRNA for differentiating between AD and controls have been found:

-   -   hsa-miR-1285-5p brain-mir-112 hsa-miR-5010-3p hsa-miR-151a-3p         hsa-let-7f-5p,     -   hsa-miR-3127-3p hsa-miR-1285-5p hsa-miR-425-5p hsa-miR-148b-5p         hsa-miR-144-5p,     -   hsa-miR-3127-3p hsa-miR-3157-3p hsa-miR-148b-5p hsa-miR-151a-3p         hsa-miR-144-5p,     -   hsa-miR-3127-3p hsa-miR-1285-5p hsa-miR-425-5p hsa-miR-151a-3p         hsa-miR-144-5p,     -   hsa-miR-1285-5p brain-mir-112 hsa-miR-5010-3p hsa-miR-151a-3p         hsa-let-7a-5p,     -   hsa-miR-5001-3p hsa-miR-1285-5p hsa-miR-425-5p hsa-miR-148b-5p         hsa-miR-144-5p,     -   hsa-miR-3127-3p hsa-miR-1285-5p hsa-miR-148b-5p hsa-miR-151a-3p         hsa-miR-144-5p,     -   hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-425-5p hsa-miR-148b-5p         hsa-miR-144-5p,     -   hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-151a-3p hsa-miR-144-5p         hsa-let-7a-5p,     -   hsa-miR-1285-5p brain-mir-112 hsa-miR-425-5p hsa-miR-151a-3p         hsa-miR-144-5p,     -   hsa-miR-5001-3p hsa-miR-1285-5p brain-mir-112 hsa-miR-151a-3p         hsa-let-7f-5p,     -   hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-148b-5p hsa-miR-144-5p         hsa-let-7f-5p,     -   hsa-miR-1285-5p hsa-miR-3157-3p hsa-miR-148b-5p hsa-miR-151a-3p         hsa-miR-144-5p,     -   hsa-miR-5001-3p hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-151a-3p         hsa-let-7f-5p,     -   brain-mir-431 hsa-miR-1285-5p hsa-miR-3157-3p hsa-miR-151a-3p         hsa-miR-144-5p,     -   hsa-miR-3127-3p hsa-miR-1285-5p brain-mir-112 hsa-miR-425-5p         hsa-miR-151a-3p,     -   hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-151a-3p hsa-miR-144-5p         hsa-let-7f-5p,     -   hsa-miR-550a-5p hsa-miR-1285-5p brain-mir-112 hsa-miR-151a-3p         hsa-let-7f-5p,     -   hsa-miR-1285-5p brain-mir-112 hsa-miR-148b-5p hsa-miR-151a-3p         hsa-miR-144-5p, and     -   hsa-miR-5001-3p brain-mir-112 hsa-miR-5010-3p hsa-miR-151a-3p         hsa-let-7f-5p.

These are further preferred combinations for classifying a sample of a patient suffering from or at risk of developing Alzheimer's Disease or diagnosing AD, or predicting an outcome of AD (ca. Table 3)

TABLE 3 Further preferred signatures for diagnosing AD. Mean mean mean mean AD Signature AUC AD Control MCI replication miRNA 1 miRNA 2 miRNA 3 miRNA 4 miRNA 5 sig #1 0.011 1.123 −0.019 0.557 1.190 hsa-miR- brain-mir- hsa-miR- hsa-miR- hsa-let- 1285-5p 112 5010-3p 151a-3p 7f-5p sig #2 0.011 1.054 −0.012 0.549 1.281 hsa-miR- hsa-miR- hsa-miR- hsa-miR- hsa-miR- 3127-3p 1285-5p 425-5p 148b-5p 144-5p sig #3 0.015 1.101 −0.028 0.454 1.137 hsa-miR- hsa-miR- hsa-miR- hsa-miR- hsa-miR- 3127-3p 3157-3p 148b-5p 151a-3p 144-5p sig #4 0.015 1.097 −0.015 0.663 1.325 hsa-miR- hsa-miR- hsa-miR- hsa-miR- hsa-miR- 3127-3p 1285-5p 425-5p 151a-3p 144-5p sig #5 0.016 1.111 −0.020 0.561 1.187 hsa-miR- brain-mir- hsa-miR- hsa-miR- hsa-let- 1285-5p 112 5010-3p 151a-3p 7a-5p sig #6 0.018 1.078 0.003 0.515 1.318 hsa-miR- hsa-miR- hsa-miR- hsa-miR- hsa-miR- 5001-3p 1285-5p 425-5p 148b-5p 144-5p sig #7 0.020 1.097 −0.015 0.490 1.140 hsa-miR- hsa-miR- hsa-miR- hsa-miR- hsa-miR- 3127-3p 1285-5p 148b-5p 151a-3p 144-5p sig #8 0.020 1.062 −0.010 0.493 1.299 hsa-miR- hsa-miR- hsa-miR- hsa-miR- hsa-miR- 1285-5p 5010-3p 425-5p 148b-5p 144-5p sig #9 0.021 1.152 0.002 0.645 1.332 hsa-miR- hsa-miR- hsa-miR- hsa-miR- hsa-let- 1285-5p 5010-3p 151a-3p 144-5p 7a-5p sig #10 0.021 1.139 −0.014 0.614 1.217 hsa-miR- brain-mir- hsa-miR- hsa-miR- hsa-miR- 1285-5p 112 425-5p 151a-3p 144-5p sig #11 0.021 1.139 −0.006 0.579 1.209 hsa-miR- hsa-miR- brain-mir- hsa-miR- hsa-let- 5001-3p 1285-5p 112 151a-3p 7f-5p sig #12 0.021 1.120 0.006 0.527 1.291 hsa-miR- hsa-miR- hsa-miR- hsa-miR- hsa-let- 1285-5p 5010-3p 148b-5p 144-5p 7f-5p sig #13 0.021 1.111 −0.015 0.400 1.031 hsa-miR- hsa-miR- hsa-miR- hsa-miR- hsa-miR- 1285-5p 3157-3p 148b-5p 151a-3p 144-5p sig #14 0.021 1.105 −0.004 0.572 1.335 hsa-miR- hsa-miR- hsa-miR- hsa-miR- hsa-let- 5001-3p 1285-5p 5010-3p 151a-3p 7f-5p sig #15 0.021 1.098 −0.021 0.492 0.767 brain-mir- hsa-miR- hsa-miR- hsa-miR- hsa-miR- 431 1285-5p 3157-3p 151a-3p 144-5p sig #16 0.021 1.056 −0.038 0.579 1.180 hsa-miR- hsa-miR- brain-mir- hsa-miR- hsa-miR- 3127-3p 1285-5p 112 425-5p 151a-3p sig #17 0.022 1.164 0.003 0.641 1.335 hsa-miR- hsa-miR- hsa-miR- hsa-miR- hsa-let- 1285-5p 5010-3p 151a-3p 144-5p 7f-5p sig #18 0.022 1.140 −0.015 0.691 0.649 hsa-miR- hsa-miR- brain-mir- hsa-miR- hsa-let- 550a-5p 1285-5p 112 151a-3p 7f-5p sig #19 0.022 1.140 −0.014 0.441 1.033 hsa-miR- brain-mir- hsa-miR- hsa-miR- hsa-miR- 1285-5p 112 148b-5p 151a-3p 144-5p sig #20 0.022 1.137 −0.016 0.576 1.333 hsa-miR- brain-mir- hsa-miR- hsa-miR- hsa-let- 5001-3p 112 5010-3p 151a-3p 7f-5p

SUPPLEMENTAL TABLE 1 a Significantly down-regulated miRNAs in AD vs. controls. SEQ ID t-test p-value NO miRNA median AD median Control single AUC 1 hsa-miR-144-5p 179.3082706767 913.7744360902 8.76E−08 0.0928030303 2 hsa-let-7f-5p 8334.1804511278 12867.954887218 7.60E−07 0.0710227273 3 hsa-let-7e-5p 4971.7669172932 8212.9360902256 8.58E−07 0.1382575758 4 hsa-let-7a-5p 8868.4511278196 15370.052631579 4.43E−06 0.0880681818 5 hsa-miR-107 2433.0413533835 4822.3984962406 1.82E−05 0.203125 6 hsa-let-7g-5p 1352.3684210526 3403.3759398496 2.69E−05 0.1259469697 7 hsa-miR-103a- 2810.8458646617 5290.1278195489 3.89E−05 0.2088068182 3p 8 hsa-miR-98 106.0864661654 217.3533834586 4.28E−05 0.1515151515 9 hsa-miR-29c-3p 40.8327067669 74.8402255639 6.87E−05 0.1922348485 10 hsa-miR-101-3p 56.1090225564 417.7105263158 0.0001143344 0.1463068182 11 hsa-miR-548h- 3.6296992481 10.0845864662 0.000139166 0.1770833333 5p 12 hsa-miR-106b- 1685.5864661654 2614.7518796993 0.0001453506 0.2097537879 3p 13 hsa-miR-15a-5p 598.484962406 1472.9962406015 0.0001554169 0.1557765152 14 hsa-miR-548g- 3.0338345865 9.6296992481 0.0002158917 0.1979166667 5p 15 hsa-miR-548ar- 3.0338345865 9.6296992481 0.0002158917 0.1979166667 5p 16 hsa-miR-548x- 3.0338345865 9.6296992481 0.0002158917 0.1979166667 5p 17 hsa-miR-548aj- 3.0338345865 9.6296992481 0.0002158917 0.1979166667 5p 18 hsa-let-7c 6147.5714285714 11249.522556391 0.0002796738 0.1661931818 19 brain-mir-394 2.8026315789 7.8364661654 0.0003164566 0.2059659091 20 hsa-miR-1294 8.765037594 25.9379699248 0.0003239282 0.2026515152 21 brain-mir-170 2.8026315789 7.8364661654 0.0003241053 0.2069128788 22 hsa-miR-199a- 4.0883458647 12.454887218 0.0003438893 0.1595643939 3p 23 brain-mir-149 2.8157894737 7.8364661654 0.000344696 0.2097537879 24 brain-mir-151 2.8157894737 7.8364661654 0.000344696 0.2097537879 25 brain-mir-370 178.4586466165 778.2894736842 0.0003625216 0.1553030303 26 hsa-miR-199b- 4.0883458647 12.6259398496 0.0003732986 0.1652462121 3p 27 brain-mir-333 2.8026315789 7.8364661654 0.0004122695 0.2069128788 28 hsa-miR-628-3p 2.954887218 7.1165413534 0.0004263003 0.2320075758 29 hsa-miR-190a 1.0488721805 5.5977443609 0.0004511324 0.1837121212 30 hsa-miR-29b-3p 11.8120300752 23.6503759398 0.0005076275 0.228219697 31 hsa-miR-660-5p 20.2537593985 72.9116541353 0.0006111848 0.1766098485 32 hsa-miR-143-3p 81.0676691729 168.0714285714 0.0006300042 0.2277462121 33 hsa-miR-548av- 3.2593984962 9.6541353383 0.0006819514 0.2196969697 5p 34 hsa-miR-548k 3.2593984962 9.6541353383 0.0006819514 0.2196969697 35 hsa-miR-29a-3p 43.6917293233 74.4943609023 0.0008592211 0.2414772727 36 hsa-miR-548i 0.1992481203 1.1090225564 0.0009595931 0.1482007576 37 hsa-miR-17-3p 32.5563909774 80.7781954887 0.0015924698 0.1410984848 38 brain-mir-398 10.0338345865 29.5526315789 0.0016819805 0.1964962121 39 hsa-miR-148a- 274.1748120301 845.5263157895 0.001762298 0.1586174242 3p 40 hsa-miR-126-3p 39.045112782 108.8195488722 0.0028031688 0.2135416667 41 brain-mir-150 6.4266917293 19.4812030075 0.0034501841 0.2201704545 42 hsa-let-7i-5p 2907.4210526316 6027.2030075188 0.0034616244 0.2059659091 43 hsa-miR-33b-5p 0.227443609 2.1240601504 0.0035364268 0.2580492424 44 hsa-miR-3200- 16.765037594 23.5037593985 0.0045456431 0.3233901515 3p 45 hsa-miR-548o- 0.3834586466 1.7593984962 0.0047156877 0.2831439394 5p 46 hsa-miR-152 11.2142857143 22.2312030075 0.0052379113 0.1983901515 47 hsa-miR-548am- 0.4887218045 1.7593984962 0.0053080221 0.2878787879 5p 48 hsa-miR-548au- 0.4887218045 1.7593984962 0.0053080221 0.2878787879 5p 49 hsa-miR-548c- 0.4887218045 1.7593984962 0.0053080221 0.2878787879 5p 50 brain-mir-248S 0.2443609023 0.9285714286 0.0065438684 0.2547348485 51 hsa-miR-215 2042.3909774436 2997.969924812 0.008661199 0.3072916667 52 hsa-miR-340-5p 7.5977443609 21.984962406 0.0088183152 0.271780303 53 hsa-miR-1301 6.7330827068 9.5488721805 0.0089721175 0.2845643939 54 brain-mir-145 13.9511278195 17.7556390977 0.008979579 0.3143939394 55 hsa-miR-504 0.3834586466 1.8026315789 0.0093874443 0.3697916667

SUPPLEMENTAL TABLE 1 b Significantly up-regulated miRNAs in AD vs. controls. SEQ ID t-test p-value NO miRNA median AD median Control single AUC 56 hsa-miR-30d-5p 11759.6691729323 7038.4962406015 9.25E−12 0.8863636364 57 hsa-miR-4781- 20.1597744361 10.0714285714 8.76E−10 0.8726325758 3p 58 hsa-miR-151a- 3303.037593985 1892.6616541353 3.49E−08 0.8645833333 3p 59 brain-mir-112 10.242481203 3.2687969925 4.77E−08 0.8735795455 60 hsa-miR-28-3p 1009.6466165414 537.7894736842 1.17E−07 0.7845643939 61 hsa-miR-26b-3p 73.6240601504 29.2105263158 1.18E−07 0.8333333333 62 hsa-miR-1468 80.1296992481 34.6466165414 9.00E−07 0.7732007576 63 hsa-miR-128 1204.3533834587 761.5676691729 9.93E−07 0.8238636364 64 hsa-miR-550a- 61.6052631579 39.4135338346 1.93E−06 0.8143939394 5p 65 hsa-miR-5010- 134.5263157895 77.8684210526 2.52E−06 0.8191287879 3p 66 hsa-miR-148b- 24.1278195489 12.8928571429 2.85E−06 0.8096590909 5p 67 brain-mir-395 7.8759398496 4.3233082707 3.18E−06 0.7935606061 68 brain-mir-308 7.8759398496 4.3233082707 3.18E−06 0.7935606061 69 hsa-miR-1285- 7.0695488722 3.2030075188 3.47E−06 0.7954545455 5p 70 hsa-miR-5001- 14.8796992481 7.0714285714 4.41E−06 0.8077651515 3p 71 hsa-miR-3127- 5.8421052632 2.4718045113 5.13E−06 0.7883522727 3p 72 hsa-miR-3157- 7.3778195489 3.1616541353 7.70E−06 0.8181818182 3p 73 brain-mir-431 6.2462406015 2.9436090226 8.30E−06 0.7869318182 74 hsa-miR-550a- 53.4661654135 31.9680451128 8.51E−06 0.7987689394 3-5p 75 hsa-miR-361-5p 51.6973684211 28.5733082707 1.18E−05 0.7940340909 76 brain-mir-83 160.5808270677 95.3872180451 1.37E−05 0.7367424242 77 hsa-miR-589-5p 305.6390977444 227.015037594 1.54E−05 0.7698863636 78 hsa-miR-425-5p 5290.1278195489 2907.4210526316 1.61E−05 0.8020833333 79 hsa-miR-30a-5p 10739.3759398496 7557.4210526316 2.66E−05 0.7826704545 80 brain-mir-79 3.5206766917 1.3026315789 2.85E−05 0.7552083333 81 brain-mir-80 3.5206766917 1.3026315789 2.85E−05 0.7552083333 82 hsa-miR-330-5p 10.7312030075 6.3402255639 3.46E−05 0.7722537879 83 hsa-miR-186-5p 4206.2932330827 2433.0413533835 3.46E−05 0.775094697 84 brain-mir-390 5.4191729323 3.1428571429 3.85E−05 0.7618371212 85 hsa-let-7d-3p 391.4060150376 208.9398496241 3.95E−05 0.7069128788 86 hsa-miR-328 396.6992481203 204.6898496241 4.08E−05 0.7168560606 87 hsa-miR-30c-5p 3195.7781954887 1563.7631578947 4.79E−05 0.7769886364 88 brain-mir-200 30.3740601504 15.8233082707 5.41E−05 0.7665719697 89 hsa-miR-363-3p 6371.4285714286 4971.7669172932 5.51E−05 0.7552083333 90 hsa-miR-339-3p 125.3120300752 87.8345864662 5.67E−05 0.7471590909 91 brain-mir-114 1009.6466165414 543.5526315789 5.76E−05 0.6856060606 92 hsa-miR-942 512.7142857143 306.2894736842 6.12E−05 0.6851325758 93 hsa-miR-345-5p 470.6090225564 317.9210526316 6.17E−05 0.7481060606 94 brain-mir-247 2997.969924812 1634.6879699248 7.23E−05 0.7315340909 95 hsa-miR-4742- 43.2030075188 27.6635338346 7.99E−05 0.7201704545 3p 96 brain-mir-314 3614.8045112782 2124.5751879699 8.13E−05 0.7324810606 97 brain-mir-12 2433.0413533835 1370.5338345865 9.13E−05 0.7220643939 98 brain-mir-232 75.0733082707 39.9285714286 9.70E−05 0.6799242424 99 brain-mir-424S 4.8571428571 2.1503759398 0.0001134253 0.7608901515 100 brain-mir-219 28.5751879699 15.7819548872 0.0001441433 0.7736742424 101 hsa-miR-10a-5p 827.0977443609 443.9586466165 0.0001696328 0.7334280303 102 hsa-miR-3605- 280.9135338346 187.6466165414 0.0001817728 0.6837121212 3p 103 brain-mir-52 9.2406015038 4.6503759398 0.0002065404 0.7817234848 104 brain-mir-53 6.7462406015 3.8909774436 0.0002097674 0.7604166667 105 hsa-miR-3157- 0.3721804511 0.1240601504 0.0002118311 0.7277462121 5p 106 brain-mir-41S 10.5733082707 5.9191729323 0.0002570966 0.7803030303 107 brain-mir-201 15.4248120301 9.5469924812 0.000293033 0.7291666667 108 hsa-miR-5006- 2.5921052632 1.4210526316 0.0003127522 0.743844697 3p 109 hsa-miR-4659a- 7.2255639098 4.0977443609 0.0003606508 0.7447916667 3p 110 brain-mir-279 10.1334586466 5.1541353383 0.000437069 0.6955492424 111 brain-mir-111 986.477443609 590.4022556391 0.0004713764 0.7504734848 112 brain-mir-88 2.3646616541 1.3778195489 0.0005681084 0.6912878788 113 brain-mir-251 1.8909774436 0.8458646617 0.0005688548 0.7296401515 114 hsa-miR-4435 51.0902255639 33.9661654135 0.0005693209 0.7230113636 115 hsa-miR-5690 11.3984962406 7.5281954887 0.0005745024 0.7253787879 116 brain-mir-166 2.4210526316 1.0921052632 0.0006242931 0.7149621212 117 brain-mir-193 1.6127819549 0.8402255639 0.0006339444 0.7002840909 118 hsa-miR-625-5p 7.3590225564 4.3571428571 0.0006972852 0.7575757576 119 hsa-miR-10b-5p 683.6766917293 406.3007518797 0.0008299916 0.7168560606 120 brain-mir-299 3.9586466165 1.7857142857 0.000839426 0.7069128788 121 brain-mir-153 0.5751879699 0.1428571429 0.0008478946 0.6860795455 122 hsa-miR-758 0.5939849624 0.1240601504 0.0008889247 0.7589962121 123 hsa-miR-30a-3p 114.6278195489 67.3947368421 0.0009850641 0.7357954545 124 brain-mir-220 36.4530075188 24.4511278195 0.0010085027 0.7182765152 125 brain-mir-392 5.5695488722 3.1447368421 0.001117105 0.6586174242 126 brain-mir-102 34.0526315789 22.9229323308 0.0011430551 0.7571022727 127 hsa-let-7b-3p 47.2894736842 26.0338345865 0.0011483131 0.7471590909 128 hsa-miR-340-3p 23.6879699248 9.4248120301 0.0011789284 0.7651515152 129 hsa-miR-484 21682.0451127819 14260.5789473684 0.0012569269 0.7211174242 130 hsa-miR-30e-3p 169.3082706767 121.1917293233 0.0013440534 0.7381628788 131 brain-mir-72S 0.4436090226 0.1240601504 0.0014225572 0.7348484848 132 hsa-miR-371b- 4.7142857143 2.2706766917 0.0014389281 0.7258522727 5p 133 hsa-miR-5581- 2.3327067669 1.5620300752 0.0015546337 0.7064393939 3p 134 brain-mir-399 19.1616541353 12.7706766917 0.0015845513 0.6619318182 135 brain-mir-403 4.1842105263 2.8364661654 0.0016408632 0.6695075758 136 brain-mir-73 21.1766917293 12.992481203 0.0016958209 0.6922348485 137 brain-mir-190 4.3233082707 2.3590225564 0.0020611484 0.6903409091 138 brain-mir-188 4.3233082707 2.3590225564 0.0020611484 0.6903409091 139 brain-mir-189 4.3233082707 2.3590225564 0.0020611484 0.6903409091 140 brain-mir-192 4.3233082707 2.3590225564 0.0020611484 0.6903409091 141 brain-mir-311 382.2819548872 266.9248120301 0.0022861501 0.6373106061 142 brain-mir-161 17.4887218045 10.5 0.0024185375 0.7424242424 143 hsa-miR-3074- 24.015037594 15.7105263158 0.002419588 0.740530303 5p 144 hsa-miR-30b-5p 443.9586466165 292.2105263158 0.0024240637 0.712594697 145 hsa-miR-576-5p 291.3834586466 207.484962406 0.0024324256 0.7215909091 146 brain-mir-23 16.2218045113 11.3665413534 0.0024712736 0.71875 147 hsa-miR-943 2.0789473684 1.3984962406 0.0025973005 0.6903409091 148 brain-mir-351 0.272556391 0.1278195489 0.0026770024 0.6439393939 149 hsa-miR-4772- 1.0601503759 0.219924812 0.0030588227 0.6884469697 3p 150 brain-mir-319 4.954887218 3.6860902256 0.0031658495 0.6912878788 151 hsa-miR-937 13.8984962406 8.4323308271 0.0032014572 0.6174242424 152 hsa-miR-181a- 222.4135338346 173.3458646617 0.0034658731 0.6770833333 2-3p 153 hsa-miR-4755- 6.4661654135 4.0789473684 0.003589103 0.6590909091 5p 154 hsa-miR-3909 7.7011278195 4.1691729323 0.0036634327 0.7466856061 155 hsa-miR-1260b 548 436.8947368421 0.0037982461 0.640625 156 brain-mir-293 3.4022556391 2.0056390977 0.0043533661 0.6879734848 157 brain-mir-160 13.1635338346 9.3646616541 0.0047314115 0.6496212121 158 hsa-miR-2110 37.5056390977 20.3082706767 0.0048976896 0.7755681818 159 hsa-miR-584-3p 1.6184210526 0.8289473684 0.0049666999 0.6401515152 160 brain-mir-129 1.2312030075 0.8139097744 0.0052865283 0.6557765152 161 hsa-miR-1280 2.8233082707 1.1860902256 0.0054091313 0.6519886364 162 hsa-miR-3180- 1.0939849624 0.515037594 0.0064691451 0.6557765152 5p 163 hsa-miR-668 0.3289473684 0.1390977444 0.0064710752 0.640625 164 hsa-miR-4512 2.0112781955 0.787593985 0.0068965461 0.6638257576 165 hsa-miR-641 10.0902255639 7.5620300752 0.0069660105 0.6619318182 166 hsa-miR-1233 2.0601503759 0.9285714286 0.007463631 0.6586174242 167 hsa-miR-378a- 10.0263157895 5.4755639098 0.0075454956 0.7149621212 5p 168 hsa-miR-26a-5p 5634.0676691729 4206.2932330827 0.007829731 0.6789772727 169 brain-mir-258 5.6973684211 0.8233082707 0.0079015891 0.7201704545 170 hsa-miR-1260a 553.045112782 456.4210526316 0.0091301492 0.6070075758

SUPPLEMENTAL TABLE 2 Newly discovered miRNA markers SEQ ID NO miRNA Sequence 126 brain-mir-102 UAUGGAGGUCUCUGUCUGGCU 111 brain-mir-111 CACUGCUAAAUUUGGCUGGCUU  59 brain-mir-112 AGCUCUGUCUGUGUCUCUAGG  91 brain-mir-114 CACUGCAACCUCUGCCUCCGGU  97 brain-mir-12 ACUCCCACUGCUUGACUUGACUAG 160 brain-mir-129 CAUGGUCCAUUUUGCUCUGCU  54 brain-mir-145 AAGCACUGCCUUUGAACCUGA  23 brain-mir-149 AAAAGUAAUCGCACUUUUUG  41 brain-mir-150 UGAGGUAGUAGGUGGUGUGC  24 brain-mir-151 AAAAGUAAUCGCACUUUUUG 121 brain-mir-153 CCUCUUCUCAGAACACUUCCUGG 157 brain-mir-160 CACUGCAACCUCUGCCUCC 142 brain-mir-161 CUUCGAAAGCGGCUUCGGCU 116 brain-mir-166 CUGGCUGCUUCCCUUGGUCU  21 brain-mir-170 AAAAGUAAUGGCAGUUUUUG 138 brain-mir-188 CCUGACCCCCAUGUCGCCUCUGU 139 brain-mir-189 CCUGACCCCCAUGUCGCCUCUGU 137 brain-mir-190 CCUGACCCCCAUGUCGCCUCUGU 140 brain-mir-192 CCUGACCCCCAUGUCGCCUCUGU 117 brain-mir-193 AUCCCUUUAUCUGUCCUCUAGG  88 brain-mir-200 UUCCUGGCUCUCUGUUGCACA 107 brain-mir-201 CACCCCACCAGUGCAGGCUG 100 brain-mir-219 UCAAGUGUCAUCUGUCCCUAGG 124 brain-mir-220 UCCGGAUCCGGCUCCGCGCCU 146 brain-mir-23 UUAGUGGCUCCCUCUGCCUGCA  98 brain-mir-232 UUGCUCUGCUCUCCCUUGUACU  94 brain-mir-247 ACGCCCACUGCUUCACUUGACUAG  50 brain-mir-248S GGCGGCGGAGGCGGCGGUG 113 brain-mir-251 UGGCCCAAGACCUCAGACC 169 brain-mir-258 AUCCCACCCCUGCCCCCA 110 brain-mir-279 AUCCCACCGCUGCCACAC 156 brain-mir-293 UUGGUGAGGACCCCAAGCUCGG 120 brain-mir-299 CAUGCCACUGCACUCCAGCCU  68 brain-mir-308 CACUGCACUCCAGCCUGGGUGA 141 brain-mir-311 CACUGCAACCUCUGCCUCCCGA  96 brain-mir-314 ACUCCCACUGCUUCACUUGAUUAG 150 brain-mir-319 CUGCACUCCAGCCUGGGCGA  27 brain-mir-333 AAAAGUAAUCGCAGGUUUUG 148 brain-mir-351 UGUCUUGCUCUGUUGCCCAGGU  25 brain-mir-370 GGCUGGUCUGAUGGUAGUGGGUUA  84 brain-mir-390 ACUGCAACCUCCACCUCCUGGGU 125 brain-mir-392 CCCGCCUGUCUCUCUCUUGCA  19 brain-mir-394 AAAAGUAAUCGUAGUUUUUG  67 brain-mir-395 CACUGCACUCCAGCCUGGGUGA  38 brain-mir-398 GGCUGGUCCGAGUGCAGUGGUGUU 134 brain-mir-399 CACUGCAACCUCUGCCUCC 135 brain-mir-403 AAAGACUUCCUUCUCUCGCCU 106 brain-mir-41S CCCCGCGCAGGUUCGAAUCCUG  99 brain-mir-424S CACUGCACUCCAGCCUGGGUA  73 brain-mir-431 CUCGGCCUUUGCUCGCAGCACU 103 brain-mir-52 CUGCACUCCAGCCUGGGCGAC 104 brain-mir-53 CCCAGGACAGUUUCAGUGAUG 131 brain-mir-72S GACCACACUCCAUCCUGGGC 136 brain-mir-73 UCCGGAUGUGCUGACCCCUGCG  80 brain-mir-79 CACUGCACUCCAGCCUGGCU  81 brain-mir-80 CACUGCACUCCAGCCUGGCU  76 brain-mir-83 CAGGGUCUCGUUCUGUUGCC 112 brain-mir-88 UCUUCACCUGCCUCUGCCUGCA

SUPPLEMENTAL TABLE 3 Significantly up- or down-regulated miRNAs in MCI vs. controls. SEQ ID median t-test p-value NO Marker median MCI Control single AUC 171 hsa-miR-29c-3p 31.34210526 74.84022556 1.39E−07 0.061363636 172 hsa-miR-29a-3p 39.20676692 74.4943609 2.00E−06 0.093181818 173 hsa-let-7e-5p 5465.075188 8212.93609 5.97E−06 0.139772727 174 hsa-let-7a-5p 9288.364662 15370.05263 1.19E−05 0.110227273 175 hsa-let-7f-5p 8601.315789 12867.95489 1.48E−05 0.1125 176 hsa-miR-29b-3p 9.746240602 23.65037594 9.48E−05 0.160227273 177 hsa-miR-98 98.17293233 217.3533835 0.00019379 0.152272727 178 hsa-miR-425-5p 5634.067669 2907.421053 0.000351963 0.818181818 179 hsa-miR-223-3p 328.8571429 470.6090226 0.000468269 0.230681818 180 hsa-miR-181a-2- 241.5451128 173.3458647 0.000505662 0.805681818 3p 181 hsa-miR-148b-3p 137.6541353 279.3120301 0.000811319 0.194318182 182 brain-mir-145 9.477443609 17.7556391 0.000969848 0.209090909 183 hsa-miR-548h-5p 4.864661654 10.08458647 0.000996949 0.198863636 184 hsa-miR-550a-5p 64.54323308 39.41353383 0.001127581 0.807954545 185 hsa-miR-374b-5p 10.30639098 20.54511278 0.001150103 0.222727273 186 hsa-miR-339-3p 126.4360902 87.83458647 0.00120356 0.811363636 187 hsa-miR-3661 1.357142857 3.716165414 0.001208331 0.210227273 188 brain-mir-190 6.342105263 2.359022556 0.001522223 0.818181818 189 brain-mir-188 6.342105263 2.359022556 0.001522223 0.818181818 190 brain-mir-189 6.342105263 2.359022556 0.001522223 0.818181818 191 brain-mir-192 6.342105263 2.359022556 0.001522223 0.818181818 192 hsa-miR-550a-3- 54.72368421 31.96804511 0.001581747 0.759090909 5p 193 hsa-miR-199a-3p 4.171052632 12.45488722 0.001641108 0.204545455 194 hsa-miR-199b-3p 4.221804511 12.62593985 0.001650922 0.205681818 195 hsa-miR-660-5p 35.97744361 72.91165414 0.001678456 0.221590909 196 hsa-miR-190a 1.609022556 5.597744361 0.001784374 0.204545455 197 brain-mir-220 48.59022556 24.45112782 0.002184462 0.790909091 198 hsa-miR-548g-5p 3.447368421 9.629699248 0.002357652 0.225 199 hsa-miR-548ar- 3.447368421 9.629699248 0.002357652 0.225 5p 200 hsa-miR-548x-5p 3.447368421 9.629699248 0.002357652 0.225 201 hsa-miR-548aj- 3.447368421 9.629699248 0.002357652 0.225 5p 202 brain-mir-394 2.603383459 7.836466165 0.002559946 0.215909091 203 brain-mir-149 2.603383459 7.836466165 0.002559946 0.215909091 204 brain-mir-151 2.603383459 7.836466165 0.002559946 0.215909091 205 hsa-let-7c 6816.890977 11249.52256 0.002574232 0.196590909 206 brain-mir-333 2.603383459 7.836466165 0.002690942 0.215909091 207 brain-mir-170 2.603383459 7.836466165 0.002759117 0.225 208 hsa-miR-152 12.7443609 22.23120301 0.00331602 0.222727273 209 hsa-miR-15a-5p 632.3984962 1472.996241 0.003376847 0.2 210 hsa-miR-197-5p 0.830827068 0.135338346 0.00340422 0.811363636 211 brain-mir-399 21.7518797 12.77067669 0.003703683 0.781818182 212 hsa-miR-3158-3p 433.6691729 309.3571429 0.003815704 0.732954545 213 brain-mir-150 12.15413534 19.48120301 0.003816641 0.284090909 214 hsa-miR-424-3p 194.537594 105.6146617 0.003852425 0.775 215 hsa-miR-148a-3p 578.1203008 845.5263158 0.004120012 0.240909091 216 hsa-miR-3200-3p 16.64473684 23.5037594 0.004405877 0.303409091 217 hsa-miR-628-3p 2.796992481 7.116541353 0.004410063 0.243181818 218 hsa-let-7d-5p 412.6240602 598.4849624 0.004602573 0.217045455 219 hsa-miR-4781-3p 13.96616541 10.07142857 0.004719502 0.769318182 220 brain-mir-160 17.84210526 9.364661654 0.005169293 0.768181818 221 hsa-miR-374a-5p 1.793233083 5.186090226 0.005650498 0.276136364 222 hsa-miR-338-3p 0.593984962 2.716165414 0.006017454 0.302272727 223 hsa-miR-340-5p 8.187969925 21.98496241 0.006522277 0.252272727 224 brain-mir-395 5.890977444 4.323308271 0.006577993 0.719318182 225 brain-mir-308 5.890977444 4.323308271 0.006577993 0.719318182 226 brain-mir-53 5.757518797 3.890977444 0.006988766 0.7125 227 brain-mir-229 0.417293233 1.864661654 0.007037494 0.192045455 228 hsa-miR-151a-3p 3088.518797 1892.661654 0.00727488 0.713636364 229 hsa-miR-1234 2.323308271 5.62406015 0.00831879 0.270454545 230 hsa-miR-874 6.437969925 10.02631579 0.008872069 0.269318182 231 hsa-miR-548av- 3.906015038 9.654135338 0.008945083 0.245454545 5p 232 hsa-miR-548k 3.906015038 9.654135338 0.008945083 0.245454545 233 brain-mir-101 3.883458647 6.633458647 0.009086578 0.271590909 234 hsa-miR-30d-5p 10223.82707 7038.496241 0.009299073 0.729545455 235 hsa-miR-3200-5p 22 37.82706767 0.00954828 0.282954545

SUPPLEMENTAL TABLE 4 Overview of miRNA markers, including sequence information   1 hsa-miR-144-5p GGAUAUCAUCAUAUACUGUAAG   2 hsa-let-7f-5p UGAGGUAGUAGAUUGUAUAGUU   3 hsa-let-7e-5p UGAGGUAGGAGGUUGUAUAGUU   4 hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU   5 hsa-miR-107 AGCAGCAUUGUACAGGGCUAUCA   6 hsa-let-7g-5p UGAGGUAGUAGUUUGUACAGUU   7 hsa-miR-103a-3p AGCAGCAUUGUACAGGGCUAUGA   8 hsa-miR-98 UGAGGUAGUAAGUUGUAUUGUU   9 hsa-miR-29c-3p UAGCACCAUUUGAAAUCGGUUA  10 hsa-miR-101-3p UACAGUACUGUGAUAACUGAA  11 hsa-miR-548h-5p AAAAGUAAUCGCGGUUUUUGUC  12 hsa-miR-106b-3p CCGCACUGUGGGUACUUGCUGC  13 hsa-miR-15a-5p UAGCAGCACAUAAUGGUUUGUG  14 hsa-miR-548g-5p UGCAAAAGUAAUUGCAGUUUUUG  15 hsa-miR-548ar-5p AAAAGUAAUUGCAGUUUUUGC  16 hsa-miR-548x-5p UGCAAAAGUAAUUGCAGUUUUUG  17 hsa-miR-548aj-5p UGCAAAAGUAAUUGCAGUUUUUG  18 hsa-let-7c UGAGGUAGUAGGUUGUAUGGUU  19 brain-mir-394 AAAAGUAAUCGUAGUUUUUG  20 hsa-miR-1294 UGUGAGGUUGGCAUUGUUGUCU  21 brain-mir-170 AAAAGUAAUGGCAGUUUUUG  22 hsa-miR-199a-3p ACAGUAGUCUGCACAUUGGUUA  23 brain-mir-149 AAAAGUAAUCGCACUUUUUG  24 brain-mir-151 AAAAGUAAUCGCACUUUUUG  25 brain-mir-370 GGCUGGUCUGAUGGUAGUGGGUUA  26 hsa-miR-199b-3p ACAGUAGUCUGCACAUUGGUUA  27 brain-mir-333 AAAAGUAAUCGCAGGUUUUG  28 hsa-miR-628-3p UCUAGUAAGAGUGGCAGUCGA  29 hsa-miR-190a UGAUAUGUUUGAUAUAUUAGGU  30 hsa-miR-29b-3p UAGCACCAUUUGAAAUCAGUGUU  31 hsa-miR-660-5p UACCCAUUGCAUAUCGGAGUUG  32 hsa-miR-143-3p UGAGAUGAAGCACUGUAGCUC  33 hsa-miR-548av-5p AAAAGUACUUGCGGAUUU  34 hsa-miR-548k AAAAGUACUUGCGGAUUUUGCU  35 hsa-miR-29a-3p UAGCACCAUCUGAAAUCGGUUA  36 hsa-miR-548i AAAAGUAAUUGCGGAUUUUGCC  37 hsa-miR-17-3p ACUGCAGUGAAGGCACUUGUAG  38 brain-mir-398 GGCUGGUCCGAGUGCAGUGGUGUU  39 hsa-miR-148a-3p UCAGUGCACUACAGAACUUUGU  40 hsa-miR-126-3p UCGUACCGUGAGUAAUAAUGCG  41 brain-mir-150 UGAGGUAGUAGGUGGUGUGC  42 hsa-let-7i-5p UGAGGUAGUAGUUUGUGCUGUU  43 hsa-miR-33b-5p GUGCAUUGCUGUUGCAUUGC  44 hsa-miR-3200-3p CACCUUGCGCUACUCAGGUCUG  45 hsa-miR-548o-5p AAAAGUAAUUGCGGUUUUUGCC  46 hsa-miR-152 UCAGUGCAUGACAGAACUUGG  47 hsa-miR-548am-5p AAAAGUAAUUGCGGUUUUUGCC  48 hsa-miR-548au-5p AAAAGUAAUUGCGGUUUUUGC  49 hsa-miR-548c-5p AAAAGUAAUUGCGGUUUUUGCC  50 brain-mir-248S GGCGGCGGAGGCGGCGGUG  51 hsa-miR-215 AUGACCUAUGAAUUGACAGAC  52 hsa-miR-340-5p UUAUAAAGCAAUGAGACUGAUU  53 hsa-miR-1301 UUGCAGCUGCCUGGGAGUGACUUC  54 brain-mir-145 AAGCACUGCCUUUGAACCUGA  55 hsa-miR-504 AGACCCUGGUCUGCACUCUAUC  56 hsa-miR-30d-5p UGUAAACAUCCCCGACUGGAAG  57 hsa-miR-4781-3p AAUGUUGGAAUCCUCGCUAGAG  58 hsa-miR-151a-3p CUAGACUGAAGCUCCUUGAGG  59 brain-mir-112 AGCUCUGUCUGUGUCUCUAGG  60 hsa-miR-28-3p CACUAGAUUGUGAGCUCCUGGA  61 hsa-miR-26b-3p CCUGUUCUCCAUUACUUGGCUC  62 hsa-miR-1468 CUCCGUUUGCCUGUUUCGCUG  63 hsa-miR-128 UCACAGUGAACCGGUCUCUUU  64 hsa-miR-550a-5p AGUGCCUGAGGGAGUAAGAGCCC  65 hsa-miR-5010-3p UUUUGUGUCUCCCAUUCCCCAG  66 hsa-miR-148b-5p AAGUUCUGUUAUACACUCAGGC  67 brain-mir-395 CACUGCACUCCAGCCUGGGUGA  68 brain-mir-308 CACUGCACUCCAGCCUGGGUGA  69 hsa-miR-1285-5p GAUCUCACUUUGUUGCCCAGG  70 hsa-miR-5001-3p UUCUGCCUCUGUCCAGGUCCUU  71 hsa-miR-3127-3p UCCCCUUCUGCAGGCCUGCUGG  72 hsa-miR-3157-3p CUGCCCUAGUCUAGCUGAAGCU  73 brain-mir-431 CUCGGCCUUUGCUCGCAGCACU  74 hsa-miR-550a-3-5p AGUGCCUGAGGGAGUAAGAG  75 hsa-miR-361-5p UUAUCAGAAUCUCCAGGGGUAC  76 brain-mir-83 CAGGGUCUCGUUCUGUUGCC  77 hsa-miR-589-5p UGAGAACCACGUCUGCUCUGAG  78 hsa-miR-425-5p AAUGACACGAUCACUCCCGUUGA  79 hsa-miR-30a-5p UGUAAACAUCCUCGACUGGAAG  80 brain-mir-79 CACUGCACUCCAGCCUGGCU  81 brain-mir-80 CACUGCACUCCAGCCUGGCU  82 hsa-miR-330-5p UCUCUGGGCCUGUGUCUUAGGC  83 hsa-miR-186-5p CAAAGAAUUCUCCUUUUGGGCU  84 brain-mir-390 ACUGCAACCUCCACCUCCUGGGU  85 hsa-let-7d-3p CUAUACGACCUGCUGCCUUUCU  86 hsa-miR-328 CUGGCCCUCUCUGCCCUUCCGU  87 hsa-miR-30c-5p UGUAAACAUCCUACACUCUCAGC  88 brain-mir-200 UUCCUGGCUCUCUGUUGCACA  89 hsa-miR-363-3p AAUUGCACGGUAUCCAUCUGUA  90 hsa-miR-339-3p UGAGCGCCUCGACGACAGAGCCG  91 brain-mir-114 CACUGCAACCUCUGCCUCCGGU  92 hsa-miR-942 UCUUCUCUGUUUUGGCCAUGUG  93 hsa-miR-345-5p GCUGACUCCUAGUCCAGGGCUC  94 brain-mir-247 ACGCCCACUGCUUCACUUGACUAG  95 hsa-miR-4742-3p UCUGUAUUCUCCUUUGCCUGCAG  96 brain-mir-314 ACUCCCACUGCUUCACUUGAUUAG  97 brain-mir-12 ACUCCCACUGCUUGACUUGACUAG  98 brain-mir-232 UUGCUCUGCUCUCCCUUGUACU  99 brain-mir-424S CACUGCACUCCAGCCUGGGUA 100 brain-mir-219 UCAAGUGUCAUCUGUCCCUAGG 101 hsa-miR-10a-5p UACCCUGUAGAUCCGAAUUUGUG 102 hsa-miR-3605-3p CCUCCGUGUUACCUGUCCUCUAG 103 brain-mir-52 CUGCACUCCAGCCUGGGCGAC 104 brain-mir-53 CCCAGGACAGUUUCAGUGAUG 105 hsa-miR-3157-5p UUCAGCCAGGCUAGUGCAGUCU 106 brain-mir-41S CCCCGCGCAGGUUCGAAUCCUG 107 brain-mir-201 CACCCCACCAGUGCAGGCUG 108 hsa-miR-5006-3p UUUCCCUUUCCAUCCUGGCAG 109 hsa-miR-4659a-3p UUUCUUCUUAGACAUGGCAACG 110 brain-mir-279 AUCCCACCGCUGCCACAC 111 brain-mir-111 CACUGCUAAAUUUGGCUGGCUU 112 brain-mir-88 UCUUCACCUGCCUCUGCCUGCA 113 brain-mir-251 UGGCCCAAGACCUCAGACC 114 hsa-miR-4435 AUGGCCAGAGCUCACACAGAGG 115 hsa-miR-5690 UCAGCUACUACCUCUAUUAGG 116 brain-mir-166 CUGGCUGCUUCCCUUGGUCU 117 brain-mir-193 AUCCCUUUAUCUGUCCUCUAGG 118 hsa-miR-625-5p AGGGGGAAAGUUCUAUAGUCC 119 hsa-miR-10b-5p UACCCUGUAGAACCGAAUUUGUG 120 brain-mir-299 CAUGCCACUGCACUCCAGCCU 121 brain-mir-153 CCUCUUCUCAGAACACUUCCUGG 122 hsa-miR-758 UUUGUGACCUGGUCCACUAACC 123 hsa-miR-30a-3p CUUUCAGUCGGAUGUUUGCAGC 124 brain-mir-220 UCCGGAUCCGGCUCCGCGCCU 125 brain-mir-392 CCCGCCUGUCUCUCUCUUGCA 126 brain-mir-102 UAUGGAGGUCUCUGUCUGGCU 127 hsa-let-7b-3p CUAUACAACCUACUGCCUUCCC 128 hsa-miR-340-3p UCCGUCUCAGUUACUUUAUAGC 129 hsa-miR-484 UCAGGCUCAGUCCCCUCCCGAU 130 hsa-miR-30e-3p CUUUCAGUCGGAUGUUUACAGC 131 brain-mir-72S GACCACACUCCAUCCUGGGC 132 hsa-miR-371b-5p ACUCAAAAGAUGGCGGCACUUU 133 hsa-miR-5581-3p UUCCAUGCCUCCUAGAAGUUCC 134 brain-mir-399 CACUGCAACCUCUGCCUCC 135 brain-mir-403 AAAGACUUCCUUCUCUCGCCU 136 brain-mir-73 UCCGGAUGUGCUGACCCCUGCG 137 brain-mir-190 CCUGACCCCCAUGUCGCCUCUGU 138 brain-mir-188 CCUGACCCCCAUGUCGCCUCUGU 139 brain-mir-189 CCUGACCCCCAUGUCGCCUCUGU 140 brain-mir-192 CCUGACCCCCAUGUCGCCUCUGU 141 brain-mir-311 CACUGCAACCUCUGCCUCCCGA 142 brain-mir-161 CUUCGAAAGCGGCUUCGGCU 143 hsa-miR-3074-5p GUUCCUGCUGAACUGAGCCAG 144 hsa-miR-30b-5p UGUAAACAUCCUACACUCAGCU 145 hsa-miR-576-5p AUUCUAAUUUCUCCACGUCUUU 146 brain-mir-23 UUAGUGGCUCCCUCUGCCUGCA 147 hsa-miR-943 CUGACUGUUGCCGUCCUCCAG 148 brain-mir-351 UGUCUUGCUCUGUUGCCCAGGU 149 hsa-miR-4772-3p CCUGCAACUUUGCCUGAUCAGA 150 brain-mir-319 CUGCACUCCAGCCUGGGCGA 151 hsa-miR-937 AUCCGCGCUCUGACUCUCUGCC 152 hsa-miR-181a-2-3p ACCACUGACCGUUGACUGUACC 153 hsa-miR-4755-5p UUUCCCUUCAGAGCCUGGCUUU 154 hsa-miR-3909 UGUCCUCUAGGGCCUGCAGUCU 155 hsa-miR-1260b AUCCCACCACUGCCACCAU 156 brain-mir-293 UUGGUGAGGACCCCAAGCUCGG 157 brain-mir-160 CACUGCAACCUCUGCCUCC 158 hsa-miR-2110 UUGGGGAAACGGCCGCUGAGUG 159 hsa-miR-584-3p UCAGUUCCAGGCCAACCAGGCU 160 brain-mir-129 CAUGGUCCAUUUUGCUCUGCU 161 hsa-miR-1280 UCCCACCGCUGCCACCC 162 hsa-miR-3180-5p CUUCCAGACGCUCCGCCCCACGUCG 163 hsa-miR-668 UGUCACUCGGCUCGGCCCACUAC 164 hsa-miR-4512 CAGGGCCUCACUGUAUCGCCCA 165 hsa-miR-641 AAAGACAUAGGAUAGAGUCACCUC 166 hsa-miR-1233 UGAGCCCUGUCCUCCCGCAG 167 hsa-miR-378a-5p CUCCUGACUCCAGGUCCUGUGU 168 hsa-miR-26a-5p UUCAAGUAAUCCAGGAUAGGCU 169 brain-mir-258 AUCCCACCCCUGCCCCCA 170 hsa-miR-1260a AUCCCACCUCUGCCACCA 171 hsa-miR-29c-3p UAGCACCAUUUGAAAUCGGUUA 172 hsa-miR-29a-3p UAGCACCAUCUGAAAUCGGUUA 173 hsa-let-7e-5p UGAGGUAGGAGGUUGUAUAGUU 174 hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU 175 hsa-let-7f-5p UGAGGUAGUAGAUUGUAUAGUU 176 hsa-miR-29b-3p UAGCACCAUUUGAAAUCAGUGUU 177 hsa-miR-98 UGAGGUAGUAAGUUGUAUUGUU 178 hsa-miR-425-5p AAUGACACGAUCACUCCCGUUGA 179 hsa-miR-223-3p UGUCAGUUUGUCAAAUACCCCA 180 hsa-miR-181a-2-3p ACCACUGACCGUUGACUGUACC 181 hsa-miR-148b-3p UCAGUGCAUCACAGAACUUUGU 182 brain-mir-145 AAGCACUGCCUUUGAACCUGA 183 hsa-miR-548h-5p AAAAGUAAUCGCGGUUUUUGUC 184 hsa-miR-550a-5p AGUGCCUGAGGGAGUAAGAGCCC 185 hsa-miR-374b-5p AUAUAAUACAACCUGCUAAGUG 186 hsa-miR-339-3p UGAGCGCCUCGACGACAGAGCCG 187 hsa-miR-3661 UGACCUGGGACUCGGACAGCUG 188 brain-mir-190 CCUGACCCCCAUGUCGCCUCUGU 189 brain-mir-188 CCUGACCCCCAUGUCGCCUCUGU 190 brain-mir-189 CCUGACCCCCAUGUCGCCUCUGU 191 brain-mir-192 CCUGACCCCCAUGUCGCCUCUGU 192 hsa-miR-550a-3-5p AGUGCCUGAGGGAGUAAGAG 193 hsa-miR-199a-3p ACAGUAGUCUGCACAUUGGUUA 194 hsa-miR-199b-3p ACAGUAGUCUGCACAUUGGUUA 195 hsa-miR-660-5p UACCCAUUGCAUAUCGGAGUUG 196 hsa-miR-190a UGAUAUGUUUGAUAUAUUAGGU 197 brain-mir-220 UCCGGAUCCGGCUCCGCGCCU 198 hsa-miR-548g-5p UGCAAAAGUAAUUGCAGUUUUUG 199 hsa-miR-548ar-5p AAAAGUAAUUGCAGUUUUUGC 200 hsa-miR-548x-5p UGCAAAAGUAAUUGCAGUUUUUG 201 hsa-miR-548aj-5p UGCAAAAGUAAUUGCAGUUUUUG 202 brain-mir-394 AAAAGUAAUCGUAGUUUUUG 203 brain-mir-149 AAAAGUAAUCGCACUUUUUG 204 brain-mir-151 AAAAGUAAUCGCACUUUUUG 205 hsa-let-7c UGAGGUAGUAGGUUGUAUGGUU 206 brain-mir-333 AAAAGUAAUCGCAGGUUUUG 207 brain-mir-170 AAAAGUAAUGGCAGUUUUUG 208 hsa-miR-152 UCAGUGCAUGACAGAACUUGG 209 hsa-miR-15a-5p UAGCAGCACAUAAUGGUUUGUG 210 hsa-miR-197-5p CGGGUAGAGAGGGCAGUGGGAGG 211 brain-mir-399 CACUGCAACCUCUGCCUCC 212 hsa-miR-3158-3p AAGGGCUUCCUCUCUGCAGGAC 213 brain-mir-150 UGAGGUAGUAGGUGGUGUGC 214 hsa-miR-424-3p CAAAACGUGAGGCGCUGCUAU 215 hsa-miR-148a-3p UCAGUGCACUACAGAACUUUGU 216 hsa-miR-3200-3p CACCUUGCGCUACUCAGGUCUG 217 hsa-miR-628-3p UCUAGUAAGAGUGGCAGUCGA 218 hsa-let-7d-5p AGAGGUAGUAGGUUGCAUAGUU 219 hsa-miR-4781-3p AAUGUUGGAAUCCUCGCUAGAG 220 brain-mir-160 CACUGCAACCUCUGCCUCC 221 hsa-miR-374a-5p UUAUAAUACAACCUGAUAAGUG 222 hsa-miR-338-3p UCCAGCAUCAGUGAUUUUGUUG 223 hsa-miR-340-5p UUAUAAAGCAAUGAGACUGAUU 224 brain-mir-395 CACUGCACUCCAGCCUGGGUGA 225 brain-mir-308 CACUGCACUCCAGCCUGGGUGA 226 brain-mir-53 CCCAGGACAGUUUCAGUGAUG 227 brain-mir-229 AUCCCACCUCUGCUACCA 228 hsa-miR-151a-3p CUAGACUGAAGCUCCUUGAGG 229 hsa-miR-1234 UCGGCCUGACCACCCACCCCAC 230 hsa-miR-874 CUGCCCUGGCCCGAGGGACCGA 231 hsa-miR-548av-5p AAAAGUACUUGCGGAUUU 232 hsa-miR-548k AAAAGUACUUGCGGAUUUUGCU 233 brain-mir-101 AGACCUACUUAUCUACCAACA 234 hsa-miR-30d-5p UGUAAACAUCCCCGACUGGAAG 235 hsa-miR-3200-5p AAUCUGAGAAGGCGCACAAGGU 

What is claimed is:
 1. A method of treating Alzheimer's Disease in a patient in need thereof, said method comprising administering an anti-Alzheimer's Disease therapy to the patient, wherein a blood sample from the patient exhibits an expression level value of at least one miRNA selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 7, SEQ ID NO 56, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 66, SEQ ID NO 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 73, SEQ ID NO 78, SEQ ID NO 85, SEQ ID NO 142 and SEQ ID NO 236 compared to a reference expression level value.
 2. The method according to claim 1, wherein the at least one miRNA from the sample is selected from the group consisting of SEQ ID NO 59, SEQ ID NO 65, SEQ ID NO 1, and SEQ ID NO
 56. 3. The method according to claim 1, wherein the at least one miRNA from the sample includes all seven of brain-miR-112, hsa-miR-5010-3p, hsa-miR-103a-3p, hsa-miR-107, hsa-let-7d-3p, hsa-miR-532-5p, and brain-miR-161.
 4. The method according to claim 1, wherein the at least one miRNA from the sample includes a set of 5 miRNAs selected from the group consisting of brain-mir-112 hsa-miR-5010-3p hsa-miR-1285-5p hsa-miR-151a-3p hsa-let-7f-5p, hsa-miR-3127-3p hsa-miR-1285-5p hsa-miR-425-5p hsa-miR-148b-5p hsa-miR-144-5p, hsa-miR-3127-3p hsa-miR-3157-3p hsa-miR-148b-5p hsa-miR-151a-3p hsa-miR-144-5p, hsa-miR-3127-3p hsa-miR-1285-5p hsa-miR-425-5p hsa-miR-151a-3p hsa-miR-144-5p, hsa-miR-1285-5p brain-mir-112 hsa-miR-5010-3p hsa-miR-151a-3p hsa-let-7a-5p, hsa-miR-5001-3p hsa-miR-1285-5p hsa-miR-425-5p hsa-miR-148b-5p hsa-miR-144-5p, hsa-miR-3127-3p hsa-miR-1285-5p hsa-miR-148b-5p hsa-miR-151a-3p hsa-miR-144-5p, hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-425-5p hsa-miR-148b-5p hsa-miR-144-5p, hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-151a-3p hsa-miR-144-5p hsa-let-7a-5p, hsa-miR-1285-5p brain-mir-112 hsa-miR-425-5p hsa-miR-151a-3p hsa-miR-144-5p, hsa-miR-5001-3p hsa-miR-1285-5p brain-mir-112 hsa-miR-151a-3p hsa-let-7f-5p, hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-148b-5p hsa-miR-144-5p hsa-let-7f-5p, hsa-miR-1285-5p hsa-miR-3157-3p hsa-miR-148b-5p hsa-miR-151a-3p hsa-miR-144-5p, hsa-miR-5001-3p hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-151a-3p hsa-let-7f-5p, brain-mir-431 hsa-miR-1285-5p hsa-miR-3157-3p hsa-miR-151a-3p hsa-miR-144-5p, hsa-miR-3127-3p hsa-miR-1285-5p brain-mir-112 hsa-miR-425-5p hsa-miR-151a-3p, hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-151a-3p hsa-miR-144-5p hsa-let-7f-5p, hsa-miR-550a- 5phsa-miR-1285-5p brain-mir-112 hsa-miR-151a-3p hsa-let-7f-5p, hsa-miR-1285-5p brain-mir-112 hsa-miR-148b-5p hsa-miR-151a-3p hsa-miR-144-5p, and hsa-miR-5001-3p brain-mir-112 hsa-miR-5010-3p hsa-miR-151a-3p hsa-let-7f-5p.


5. The method according to claim 4, further comprising adding the expression level values of the set of five miRNAs.
 6. The method according to claim 1, wherein the determination of the expression level value of the at least one miRNA from the sample is obtained by use of a method selected from the group consisting of a sequencing-based method, an array-based method and a PCR-based method.
 7. The method according to claim 1, wherein the expression levels values of at least 2 miRNAs in the sample are determined.
 8. The method according to claim 1, wherein the blood sample from the patient also exhibits an expression level value of at least one miRNA selected from the group consisting of hsa-miR-26b-3p, hsa-miR-26a-5p, brain-miR-161 and hsa-miR-5010-3p compared to a reference expression level value.
 9. A kit for performing the method according to claim 1, said kit comprising means for determining in said blood sample from said patient, an expression level value of at least one miRNA selected from the group consisting of miRNAs having the sequence SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 7, SEQ ID NO 56, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 66, SEQ ID NO 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 73, SEQ ID NO 78, SEQ ID NO 85, SEQ ID NO 142 and SEQ ID NO
 236. 10. The kit of claim 9, further comprising at least one reference pattern of expression levels values for comparing with the expression level values of the at least one miRNA from said sample.
 11. The method according to claim 7, wherein the expression level values of at least 3 miRNAs in the sample are determined.
 12. The method according to claim 11, wherein the expression level values of at least 4 miRNAs in the sample are determined.
 13. The method according to claim 12, wherein the expression level values of at least 5 miRNAs in the sample are determined.
 14. The method according to claim 13, wherein the expression level values of at least 6 miRNAs in the sample are determined.
 15. The method according to claim 14, wherein the expression level values of at least 7 miRNAs in the sample are determined.
 16. The method according to claim 15, wherein the expression level values of at least 8 miRNAs in the sample are determined.
 17. The method according to claim 16, wherein the expression level values of at least 9 miRNAs in the sample are determined.
 18. The method according to claim 17, wherein the expression level values of at least 10 miRNAs in the sample are determined.
 19. The method according to claim 18, wherein the expression level values of at least 12 miRNAs in the sample are determined. 